Podcasts about Grouse

As artificial intelligence (AI) tools become increasingly mainstream, they can potentially transform neurology clinical practice by improving patient care and reducing clinician workload. Critically evaluating these AI tools for clinical practice is important for successful implementation. In this episode, Katie Grouse, MD, FAAN speaks with Peter Hadar, MD, MS, coauthor of the article “Clinical Applications of Artificial Intelligence in Neurology Practice” in the Continuum® April 2025 Neuro-ophthalmology issue. Dr. Grouse is a Continuum® Audio interviewer and a clinical assistant professor at the University of California San Francisco in San Francisco, California. Dr. Hadar is an instructor of neurology at Harvard Medical School and an attending physician at the Massachusetts General Hospital in Boston, Massachusetts. Additional Resources Read the article: Clinical Applications of Artificial Intelligence in Neurology Practice Subscribe to Continuum®: shop.lww.com/Continuum Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Guest: @PeterNHadar Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about subscribing to the journal, listening to verbatim recordings of the articles, and exclusive access to interviews not featured on the podcast. Dr Grouse: This is Dr Katie Grouse. Today I'm interviewing Dr Peter Hadar about his article on clinical applications of artificial intelligence in neurology practice, which he wrote with Dr Lydia Moura. This article appears in the April 2025 Continuum issue on neuro-ophthalmology. Welcome to the podcast, and please introduce yourself to our audience. Dr Hadar: Hi, thanks for having me on, Katie. My name is Dr Peter Hadar. I'm currently an instructor over at Mass General Hospital, Harvard Medical School, and I'm excited to talk more about AI and how it's going to change our world, hopefully for the better. Dr Grouse: We're so excited to have you. The application of AI in clinical practice is such an exciting and rapidly developing topic, and I'm so pleased to have you here to talk about your article, which I found to be absolutely fascinating. To start, I'd like to hear what you hope will be the key takeaway from your article with our listeners. Dr Hadar: Yeah, thank you. The main point of the article is that AI in medicine is a tool. It's a wonderful tool that we should be cautiously optimistic about. But the important thing is for doctors, providers to be advocates on their behalf and on behalf of their patients for the appropriate use of this tool, because there are promises and pitfalls just with any tool. And I think in the article we detail a couple ways that it can be used in diagnostics, in clinical documentation, in the workflow, all ways that can really help providers. But sometimes the devil is in the details. So, we get into that as well. Dr Grouse: How did you become interested in AI and its application, specifically in the practice of neurology? Dr Hadar: When I was a kid, as most neurologists are, I was- I nerded out on a lot of sci-fi books, and I was really into Isaac Asimov and some of his robotics, which kind of talks about the philosophy of AI and how AI will be integrated in the future. As I got into neurology, I started doing research neurology and a lot of folks, if you're familiar with AI and machine learning, statistics can overlap a lot with machine learning. So slowly but surely, I started using statistical methods, machine learning methods, in some of my neurology research and kind of what brought me to where I am today. Dr Grouse: And thinking about and talking about AI, could you briefly summarize a few important terms that we might be talking about, such as artificial intelligence, generative AI, machine learning, etcetera? Dr Hadar: It's a little difficult, because some of these terms are nebulous and some of these terms are used in the lay public differently than other folks would use it. But in general, artificial intelligence is kind of the ability of machines or computers to communicate independently. It's similar to as humans would do so. And there are kind of different levels of AI. There's this very hard AI where people are worried about with kind of terminator-full ability to replicate a human, effectively. And there are other forms of narrow AI, which are actually more of what we're talking about today, and where it's very kind of specific, task-based applications of machine learning in which even if it's very complex, the AI tools, the machine learning tools are able to give you a result. And just some other terms, I guess out there. You hear a lot about generative AI. There's a lot of these companies and different algorithms that incorporate generative AI, and that usually kind of creates something, kind of from scratch, based on a lot of data. So, it can create pictures, it can create new text if you just ask it. Other terms that can be used are natural language processing, which is a big part of some of the hospital records. When AI tools read hospital records and can summarize something, if it can translate things. So, it turns human speech into these results that you look for. And I guess other terms like large language models are something that also have come into prominence and they rely a lot on natural language processing, being able to understand human speech, interpret it and come up with the results that you want. Dr Grouse: Thank you, that's really helpful. Building on that, what are some of the current clinical applications of AI that we may already be using in our neurologic practice and may not even be aware that that's what that is? Dr Hadar: It depends on which medical record system you use, but a very common one are some of the clinical alerts that people might get, although some of them are pretty basic and they can say, you know, if the sodium is this level, you get an alert. But sometimes they do incorporate fancier machine learning tools to say, here's a red flag. You really should think about contacting the patient about this. And we can talk about it as well. It might encourage burnout with all the different flags. So, it's not a perfect tool. But these sorts of things, typically in the setting of alerts, are the most common use. Sorry, and another one is in folks who do stroke, there are a lot of stroke algorithms with imaging that can help detect where the strokes occur. And that's a heavy machine learning field of image processing, image analysis for rapid detection of stroke. Dr Grouse: That's really interesting. I think my understanding is that AI has been used specifically for radiology interpretation applications for some time now. Is that right? Dr Hadar: In some ways. Actually, my background is in neuroimaging analysis, and we've been doing a lot of it. I've been doing it for years. There's still a lot of room to go, but it's really getting there in some ways. My suspicion is that in the coming years, it's going to be similar to how anesthesiologists at one point were actively bagging people in the fifties, and then you develop machines that can kind of do it for you. At some point there's going to be a prelim radiology read that is not just done by the resident or fellow, but is done by the machine. And then another radiologist would double check it and make sure. And I think that's going to happen in our lifetime. Dr Grouse: Wow, that's absolutely fascinating. What are some potential applications of AI in neurologic practice that may be most high-yield to improve patient care, patient access, and even reduce physician burnout? Dr Hadar: These are separate sort of questions, but they're all sort of interlinked. I think one of the big aspects of patient care in the last few years, especially with the electronic medical record, is patients have become much more their own advocates and we focus a lot more on patient autonomy. So, they are reaching out to providers outside of appointments. This can kind of lead to physician burnout. You have to answer all these messages through the electronic medical record. And so having, effectively, digital twins of yourself, AI version of yourself, that can answer the questions for the patient on your off times is one of the things that can definitely help with patient care. In terms of access, I think another aspect is having integrated workflows. So, being able to schedule patients efficiently, effectively, where more difficult patients automatically get one-hour appointments, patients who have fewer medical difficulties might get shorter appointments. That's another big improvement. Then finally, in terms of physician burnout, having ambient intelligence where notes can be written on your behalf and you just need to double-check them after allows you to really have a much better relationship with the patients. You can actually talk with them one on one and just focus on kind of the holistic care of the patient. And I think that's- being less of a cog in the machine and focusing on your role as a healer would be actually very helpful with the implementation of some of these AI tools. Dr Grouse: You mentioned ambient technology and specifically ambient documentation. And certainly, this is an area that I feel a lot of excitement about from many physicians, a lot of anticipation to be able to have access to this technology. And you mentioned already some of the potential benefits. What are some of the potential… the big wins, but then also potential drawbacks of ambient documentation? Dr Hadar: Just to kind of summarize, the ambient intelligence idea is using kind of an environmental AI system that, without being very obtrusive, just is able to record, able to detect language and process it, usually into notes. So, effectively like an AI scribe that is not actually in the appointment. So, the clear one is that---and I've seen this as well in my practice---it's very difficult to really engage with the patient and truly listen to what they're saying and form that relationship when you're behind a computer and behind a desk. And having that one-on-one interaction where you just focus on the patient, learn everything, and basically someone else takes notes for you is a very helpful component of it. Some of the drawbacks, though, some of it has to do with the existing technology. It's still not at the stage where it can do everything. It can have errors in writing down the medication, writing down the exact doses. It can't really, at this point, detect some of the apprehensions and some of the nonverbal cues that patients and providers may kind of state. Then there's also the big one where a lot of these are still done by startups and other companies where privacy may be an issue, and a lot of patients may feel very uncomfortable with having ambient intelligence tools introduced into their clinical visit, having a machine basically come between the doctor and the patient. But I think that over time these apprehensions will lessen. A lot of the security will improve and be strengthened, and I think that it's going to be incorporated a lot more into clinical practice. Dr Grouse: Yeah, well, we'll all be really excited to see how that technology develops. It certainly seems like it has a lot of promise. You mentioned in your article a lot about how AI can be used to improve screening for patients for certain types of conditions, and that certainly seems like an obvious win. But as I was reading the article, I couldn't help but worry that, at least in the short term, these tools could translate into more work for busy neurologists and more demand for access, which is, you know, already, you know, big problems in our field. How can tools like these, such as, like, for instance, the AI fundoscopic screening for vascular cognitive risk factors help without adding to these existing burdens? Dr Hadar: It's a very good point. And I think it's one of the central points of why we wanted to write the article is that these AI in medicine, it's, it's a tool like any other. And just like when the electronic medical record came into being, a lot of folks thought that this was going to save a lot of time. And you know, some people would say that it actually worsened things in a way. And when you use these diagnostic screening tools, there is an improvement in efficiency, there is an improvement in patient care. But it's important that doctors, patients advocate for this to be value-based and not revenue-based, necessarily. And it doesn't mean that suddenly the appointments are shorter, that now physicians have to see twice as many patients and then patients just have less of a relationship with their provider. So, it's important to just be able to integrate these tools in an appropriate way in which the provider and the patient both benefit. Dr Grouse: You mentioned earlier about the digital twin. Certainly, in your article you mentioned, you know, that idea along with the idea of the potential of development of virtual chatbot visits or in-person visits with a robot neurologist. And I read all this with equal parts, I think excitement, but horror and and fear. Can you tell us more about what these concepts are, and how far are we from seeing technology like this in our clinics, and maybe even, what are the risks we need to be thinking about with these? Dr Hadar: Yeah. So, I mean, I definitely think that we will see implementation of some of these tools in our lifetime. I'm not sure if we're going to have a full walking, talking robot doing some of the clinical visits. But I do think that, especially as we start doing a lot more virtual visits, it is very easy to imagine that there will be some sort of video AI doctor that can serve as, effectively, a digital twin of me or someone else, that can see patients and diagnose them. The idea behind the digital twin is that it's kind of like an AI version of yourself. So, while you only see one patient, an AI twin can go and see two or three other patients. They could also, if the patients send you messages, can respond to those messages in a way that you would, based on your training and that sort of thing. So, it allows for the ability to be in multiple places at once. One of the risks of this is, I guess, overreliance on the technology, where if you just say, we're just going to have a chatbot do everything for us and then not look at the results, you really run the risk of the chatbot just recommending really bad things. And there is training to be had. Maybe in fifty years the chatbot will be at the same level as a physician, but there's still a lot of room for improvement. I personally, I think that my suspicion as to where things will go are for very simple visits in the future and in our lifetime. If someone is having a cold or something like that and it goes to their primary care physician, a chatbot or something like that may be of really beneficial use. And it'll help segment out the different groups of simple diagnosis, simple treatments can be seen by these robots, these AI, these machine learning tools; and some of the more complex ones, at least for the early implementation of this will be seen by more specialized providers like neurologists and subspecialist neurologists too. Dr Grouse: That certainly seems reasonable, and it does seem that the more simple algorithmic things are always where these technologies will start, but it'll be interesting to see where things can go with more complex areas. Now I wanted to switch gears a little bit in the article- and I thought this was really important because I see it as being certainly one of the bigger drawbacks of AI, is that despite the many benefits of artificial intelligence, AI can unfortunately perpetuate systemic bias. And I'm wondering if you could tell us a little bit more about how this happened? Dr Hadar: I know I'm beating a dead horse on this, but AI is a tool like any other. And the problem with it is that what you put in is very similar to what you get out. And there's this idea in computer science of “garbage in, garbage out”. If you include a lot of data that has a lot of systemic biases already in the data, you're going to get results that perpetuate these things. So, for instance, if in dermatologic practices, if you just had a data set that included people of one skin color or one race and you attempted to train a model that would be able to detect skin cancer lesions, that model may not be easily applicable to people of other races, other ethnicities, other skin colors. And that can be very damaging for care. And it can actually really, really hurt the treatments for a lot of the patients. So that is one of the, kind of, main components of the systemic biases in AI. The way we mitigate them is by being aware of it and actually implementing, I guess, really hard stops on a lot of these tools before they get into practice. Being sure, did your data set include this breakdown of sex and gender, of race and ethnicity? So that the stuff you have in the AI tool is not just a very narrow, focused application, but can be generalized to a large population, not just of one community, one ethnic group, racial group, one country, but can really be generalized throughout the world for many patients. Dr Grouse: The first step is being aware of it, and hopefully these models will be built thoughtfully to help mitigate this as much as possible. I wanted to ask as well, another concern about AI is the safety of private data. And I'm wondering, as we're starting to do things like use ambient documentation, AI scribe, and other types of technologies like this, what can we tell our patients who are concerned about the safety of their personal data collected via these programs, particularly when they're being stored or used with outside companies that aren't even in our own electronic medical records system? Dr Hadar: Yeah, it's a very good question, and I think it's one of the major limitations of the current implementation of AI into clinical practice, because we still don't really have great standards---medical standards, at least---for storing this data, how to analyze this data. And my suspicion is that at some point in the future, we're going to need to have a HIPAA compliance that's going to be updated for the 21st century, that will incorporate the appropriate use of these tools, the appropriate use of these data storage, of data storage beyond just PHI. Because there's a lot more that goes into it. I would say that the important thing for how to implement this, and for patients to be aware of, is being very clear and very open with informed consent. If you're using a company that isn't really transparent about their data security and their data sharing practices, that needs to be clearly stated to the patient. If their data is going to be shared with other people, reanalyzed in a different way, many patients will potentially consider not participating in an AI implementation in clinic. And I think the other key thing is that this should be, at least initially, an opt-in approach as opposed to an opt-out approach. So patients really have- can really decide and have an informed opinion about whether or not they want to participate in the AI implementation in medicine. Dr Grouse: Well, thank you so much for explaining that. And it does certainly sound like there's a lot of development that's going to happen in that space as we are learning more about this and the use of it becomes more prevalent. Now, I also wanted to ask, another good point that you made in your article---and I don't think comes up enough in this area, but likely will as we're using it more---AI has a cost, and some of that cost is just the high amount of data and computational processing needed to use it, as well as the effects on the environment from all this energy usage. Given this drawback of AI, how can we think about potential costs versus the benefits, the more widespread use of this technology? Or how should we be thinking about it? Dr Hadar: It's part of a balance of the costs and benefits, effectively, is that AI---and just to kind of name some of them, when you have these larger data centers that are storing all this data, it requires a lot of energy consumption. It requires actually a lot of water to cool these things because they get really hot. So, these are some of the key environmental factors. And at this point, it's not as extreme as it could be, but you can imagine, as the world transitions towards an AI future, these data centers will become huge, massive, require a lot of energy. And as long as we still use a lot of nonrenewable resources to power our world, our civilization, I think this is going to be very difficult. It's going to allow for more carbon in the atmosphere, potentially more climate change. So, being very clear about using sustainable practices for AI usage, whether it be having data centers specifically use renewable resources, have clear water management guidelines, that sort of thing will allow for AI to grow, but in a sustainable way that doesn't damage our planet. In terms of the financial costs… so, AI is not free. However, on a given computer, if you want to run some basic AI analysis, you can definitely do it on any laptop you have and sometimes even on your phone. But for some of these larger models, kind of the ones that we're talking about in the medical field, it really requires a lot of computational power. And this stuff can be very expensive and can get very expensive very quickly, as anyone who's used any of these web service providers can attest to. So, it's very important to be clear-eyed about problems with implementation because some of these costs can be very prohibitive. You can run thousands and you can quickly rack up a lot of money for some very basic analysis if you want to do it in a very rapid way, in a very effective way. Dr Grouse: That's a great overview. You know, something that I think we're all going to be having to think about a lot more as we're incorporating these technologies. So, important conversations I hope we're all having, and in our institutions as we're making these decisions. I wanted to ask, certainly, as some of our listeners who may be still in the training process are hearing you talk about this and are really excited about AI and implementation of technology in medicine, what would you recommend to people who want to pursue a career in this area as you have done? Dr Hadar: So, I think one of the important things for trainees to understand are, there are different ways that they can incorporate AI into their lives going forward as they become more seasoned doctors. There are clinical ways, there are research ways, there are educational ways. A lot of the research ways, I'm one of the researchers, you can definitely incorporate AI. You can learn online. You can learn through books about how to use machine learning tools to do your analysis, and it can be very helpful. But I think one of the things that is lacking is a clinician who can traverse both the AI and patient care fields and be able to introduce AI in a very effective way that really provides value to the patients and improves the care of patients. So that means if a hospital system that a trainee is eventually part of wants to implement ambient technology, it's important for physicians to understand the risks, the benefits, how they may need to adapt to this. And to really advocate and say, just because we have this ambient technology doesn't mean now we see fifty different patients, and then you're stuck with the same issue of a worse patient-provider relationship. One of the reasons I got into medicine was to have that patient-provider interaction to not only be kind of a cog in the hospital machine, but to really take on a role as a healer and a physician. And one of the benefits of these AI tools is that in putting the machine in medicine, you can also put the humanity back in medicine at times. And I think that's a key component that trainees need to take to heart. Dr Grouse: I really appreciate you going into that, and sounds like there's certainly need. Hoping some of our listeners today will consider careers in pursuing AI and other types of technologies in medicine. I really appreciate you coming to talk with us today. I think this is just such a fascinating topic and an area that everybody's really excited about, and hoping that we'll be seeing more of this in our lives and hopefully improving our clinical practice. Thank you so much for talking to us about your article on AI in clinical neurology. It was a fascinating topic and I learned a lot. Dr Hadar: Thank you very much. I really appreciate the conversation, and I hope that trainees, physicians, and others will gain a lot and really help our patients through this. Dr Grouse: So again, today I've been interviewing Dr Peter Hadar about his article on clinical applications of artificial intelligence in neurology practice, which he wrote with Dr Lydia Moura. This article appears in the most recent issue of Continuum on neuro-ophthalmology. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. Thank you for listening to Continuum Audio.

In this episode of the Birdshot podcast, host Nick Larson welcomes Lars Jacob, a seasoned hunter and shotgun fitting expert. They discuss hunting conditions in Vermont, the impacts of weather on grouse populations, and the challenges of grouse hunting. They also delve into the intricacies of shotgun fitting, the importance of practice for instinctive shooting, and the allure of vintage guns, particularly British and American models. The conversation rounds off with Lars sharing his experiences and insights into gun fitting, techniques, and some exciting upcoming events. 00:00 Introduction and Weather Update 03:01 Grouse Population and Habitat Challenges 04:15 Impact of West Nile Virus on Grouse 07:30 Cyclical Nature of Grouse Populations 08:20 Changes in Vermont's Habitat and Logging Practices 12:05 Public Land Grouse Hunting Tips 12:36 Grouse Diet and Seasonal Behavior 19:11 Historical Changes in Vermont's Landscape 22:19 Turkey Hunting Legacy and Techniques 41:25 Understanding Turkey Behavior and Hunting Techniques 42:53 The Evolution of Turkey Hunting Methods 43:33 The Importance of Patience in Turkey Hunting 45:04 Introduction to the Northeast Side by Side Classic Event 46:17 Highlights of the Northeast Side by Side Classic 47:25 The Art of Gun Fitting 51:41 The Process of Gun Fitting 01:01:52 Challenges and Techniques in Wing Shooting 01:08:47 The Value of Vintage Guns 01:19:06 Conclusion and Contact Information FOLLOW | @larsjacobwingshooting CONTACT | Lars Jacob at 802-289-2002 LISTEN | to Episode #167 and #277 with Lars Jacob SUPPORT | patreon.com/birdshot Follow us | @birdshot.podcast Use Promo Code | BSP20 to save 20% with onX Hunt Use Promo Code | BS10 to save 10% on Trulock Chokes The Birdshot Podcast is Presented By: onX Hunt, Final Rise and Upland Gun Company Learn more about your ad choices. Visit megaphone.fm/adchoices

Neuro-ophthalmic deficits significantly impair quality of life by limiting participation in employment, educational, and recreational activities. Low-vision occupational therapy can improve cognition and mental health by helping patients adjust to visual disturbances. In this episode, Katie Grouse, MD, FAAN, speaks with Sachin Kedar, MD, FAAN, author of the article “Symptomatic Treatment of Neuro-ophthalmic Visual Disturbances” in the Continuum® April 2025 Neuro-ophthalmology issue. Dr. Grouse is a Continuum® Audio interviewer and a clinical assistant professor at the University of California San Francisco in San Francisco, California. Dr. Kedar is the Cyrus H Stoner professor of ophthalmology and a professor of neurology at Emory University School of Medicine in Atlanta, Georgia. Additional Resources Read the article: Symptomatic Treatment of Neuro-ophthalmic Visual Disturbances Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Guest: @AIIMS1992 Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Grouse: This is Dr Katie Grouse. Today I'm interviewing Dr Sachin Kedar about his article on symptomatic treatment of neuro-ophthalmic visual disturbances, which appears in the April 2025 Continuum issue on neuro-ophthalmology. Welcome to the podcast, and please introduce yourself to our audience. Dr Kedar: Thank you, Katie. This is Sachin Kedar. I'm a neuro-ophthalmologist at Emory University, and I've been doing this for more than fifteen years now. I trained in both neurology and ophthalmology, with a fellowship in neuro-ophthalmology in between. It's a pleasure to be here. Dr Grouse: Well, we are so happy to have you, and I'm just so excited to be discussing this article with you, which I found to be a real treasure trove of useful clinical information on a topic that many find isn't covered enough in their neurologic training. I strongly recommend all of our listeners who work with patients with visual disturbances to check this out. I wanted to start by asking you what you hope will be the main takeaway from this article for our listeners? Dr Kedar: The most important takeaway from this article is, just keep vision on your radar when you are evaluating your patients with neurological disorders. Have a list of a few symptoms, do a basic screening vision, and ask patients about how their vision is impacting the quality of life. Things like activities of daily living, hobbies, whether they can cook, dress, ambulate, drive, read, interact with others. It is very important for us to do so because vision can be impacted by a lot of neurological diseases. Dr Grouse: What in the article do you think would come as the biggest surprise to our listeners? Dr Kedar: The fact that impairment of vision can magnify and amplify neurological deficits in a lot of what we think of as core neurological disorders should come as a surprise to most of the audience. Dr Grouse: On that note, I think it's probably helpful if you could remind us about the types of visual disturbances we should be thinking about and screening for in our patients? Dr Kedar: Patients who have neurological diseases can have a whole host of visual deficits. The simplest ones are deficits of central vision. They can have problems with their visual field. They can have abnormalities of color vision or even contrast sensitivity. A lot of our patients also complain of light sensitivity, eyes feeling tired when they're doing their usual stuff. Some of our patients can have double vision, they can have shaky vision, which leads to their sense of imbalance and maybe a fall risk to them. Dr Grouse: It's really helpful to think about all the different aspects in which vision can be affected, not just sort of the classic loss of vision. Now, your article also serves as a really important reminder, which you alluded to earlier, about how impactful visual disturbances can be on daily activities. Could you elaborate a little further on this, and particularly the various domains that can be affected when there are visual disturbances present? Dr Kedar: So, when I look at how visual disturbances affect quality of life, I look at two broad categories. One is activities of basic daily living. These would be things like, are you able to cook? Are you able to ambulate not just in your home, but in your neighborhood? Are you able to drive to your doctor's appointment or to visit with your family? Are you able to dress yourself appropriately? Are you able to visualize the clothing and choose them appropriately? And then the second category is recreational activities. Are you able to read? Are you able to watch television? Are you able to visit the theatre? Are you able to travel? Are you able to participate in group activities, be it with your family or be it with your social group? It is very important for us to ask our patients if they have problems doing any of this because it really can adversely impact the quality of life. Dr Grouse: I think, certainly with all the things we try to get through talking with our patients, this may not be something that we do spend a lot of time on. So, I think it's it is a good reminder that when we can, being able to ask about these are going to be really important and help us hit on a lot of other things we may not even realize or know to ask about. Now, I was really struck when I was reading your article by the meta-analysis that you had quoted that had showed 47% higher risk of developing dementia among the visually impaired compared to those without visual impairments. Should we be doing more in-depth visual testing on all of our patients with cognitive symptoms? Dr Kedar: This is actually the most interesting part of this article, and kind of hones in on the importance of vision in neurological disorders. Now I want to clarify that patients with visual disorders, it's not a causative influence on dementia, but if you have a patient with an underlying cognitive disorder, any kind of visual disturbance will significantly make it worse. And this has been shown in several studies, both in the neurologic and in the ophthalmological literature. So, I quoted one of the big meta-analysis over there, but studies have clearly shown that if you have these patients and treat them for their visual deficits, their cognitive indices can actually significantly improve. To answer your question, I would say a neurologist should include basic vision screening as part of every single evaluation. Now, I know it's a hard thing in, you know, these days when we are literally running on the hamster wheel, but I can assure you that it won't take you more than 2 to 3 minutes of your time to do this basic screening; in fact, you can have one of your assistants included as part of the vital signs assessment. What are these basic screening tools? Measure the visual acuity for both near and distance. Check and see if their visual field's off with the confrontation. Look at their eye movements. Are they able to move their eyes in all directions? Are the eyes stable when they're trying to fixate on a particular point? I think if you can do these basic things, you will have achieved quite a bit. Dr Grouse: That's really helpful, and thanks for going through some of the standard, or really, you know, solid basic foundation of visual testing we should be thinking about doing. I wanted to move on to some more details about the visual disturbances. You made an excellent point that there are many types of primary ophthalmologic conditions that can cause visual disturbances that we should keep in mind. So maybe not things that we think about a lot on a day-to-day basis, but, you know, are still there and very common. What are some of the most common ones, and when should we be referring them to see an ophthalmologist? Dr Kedar: So, it depends on the age group of your patient population. Now, the majority of us are adult neurologists, and so the kinds of ophthalmic conditions that we see in this population is going to be different from the pediatric age group. So in the adult population, we might see patients with uncorrected refractive error, presbyopia, patients who have cataracts creep on them, they may have glaucoma, they may have macular degeneration, and these tend to have a slightly higher incidence in the older age group. Now for those of us who are taking care of the younger population, uncorrected refractive errors, strabismus and amblyopia tend to be fairly common causes of visual deprivation in this age group. What I would encourage all of our neurologists is, make sure that your patients get a basic eye examination at least once a year. Just like you want them to go to their primary care and get an annual maintenance visit, everybody should go to the ophthalmologist or the optometrist and get a basic examination. And, if you're resourceful enough, have your patients bring a copy of that assessment. Whether it is normal or there's some abnormality, it is going to help you in the management. Dr Grouse: Absolutely. I think that's a great piece of advice, to think of it almost, like, them seeing their primary care doctor, which of course we offer encourage our patients to do, thinking of this as another very important piece of standard primary care. If a patient comes to you reporting difficulty reading due to possible visual disturbances, I'm curious, can you walk us through how you would approach this evaluation? Dr Kedar: It is not a very common presenting complaint of our patients, even in the neuro-ophthalmology clinic. It's a very rare patient that I see who comes and says, I cannot read or, I have difficulty reading. Most of the patients will come saying, oh, I cannot see. And then you have to dig in to find out, what does that actually mean? What can you not see? Is it a problem in your driving? Is it a problem in your reading? Or is it a problem that occurs at all times? Now you asked me, how do you approach this evaluation? One of the things that all of us, whether we are neurologists, ophthalmologists, or neuro-ophthalmologists, forget to do is to actually have the patient read a paragraph, a sentence, when they are in clinic. And that will give you a lot of ideas about what might actually be going wrong with the patient. Now, as far as how do I approach this evaluation, I will do a basic screening examination to make sure that their visual acuity is good for both distance and near. A lot of us tend to do either distance or near and we will miss the other parameter. You want to do a basic confrontation visual field to make sure that they do not have any subtle deficits that's impacting their ability to read. Examine the eye movements, do a fundoscopic examination. Now, once you've done this basic screening, as a neurologist, you already have some idea of whether your patient has a lesion along the visual pathways. If you suspect that this is a problem with, say, the visual pathways, ask your ophthalmology colleague to do a formal visual field assessment, and that'll pick up subtle deficits of central visual field. And lastly, don't forget higher visual function testing or cortical visual function testing. So basically, you're looking for neglect, phenomenon, or simultanagnosia, all of which tends to have an impact on reading. So, in the manuscript I have a schema of how you can approach a patient with reading difficulties, and in that ischemia you will see categories of where things can go wrong during the process of reading. And if you can approach your patient systematically through one of those domains, there's a fairly good chance that you'll be able to pick up a problem. Dr Grouse: Going a little further on to when you do identify problems with loss of central or peripheral vision, what are some strategies for symptomatic management of these types of visual disturbances? Dr Kedar: As a neurologist, if you pick up a problem with the vision, you have to send this patient to an eye care provider. The vast majority of people who have visual disturbances, it's from an eye disease. You know, as I alluded to earlier, it can be something as simple as uncorrected refractive error, and that can be fixed easily. A lot of patients in our older age group will have dry eye syndrome, which means they are unable to adequately lubricate the surface of the eye, and as a result, it degrades the quality of their vision. So, they tend to get intermittent episodes of blurred vision, or they tend to get glare. They tend to get various forms of optical aberration. Patients can have cataracts, patients can have glaucoma or macular degeneration. And in all of those instances, the goal is to treat the underlying disease, optimize the vision, and then see what the residual deficit is. By and large, if a patient has a problem with the central vision, then magnification will help them for activities that they perform at near; say, reading. Now for patients with peripheral vision problem, it's a different entity altogether. Again, once you've identified what the underlying cause is, your first goal is to treat it. So, for example, if your patient has glaucoma, which is affecting peripheral vision, you're going to treat glaucoma to make sure that the visual field does not progress. Now a lot of what happens after that is rehabilitation, and that is always geared towards the specific activities that are affected. Is it reading? Is it ambulating? Is it watching television? Is it driving? And then you can advise as a neurologist, you can advise your occupational therapist or low vision specialist and say, hey, my patient is not able to do this particular activity. Can we help them? Dr Grouse: Moving on from that, I wanted to also hit on your approach when patients have disorders of ocular motility. What are some things you can do for symptomatic management of that? Dr Kedar: So, patients with ocular motility can have two separate symptoms. Two, you know, two disabling symptoms, as they would call it. One is double vision and the other is oscillopsia, or the feeling or the visualization of the environment moving in response to your eyes not being able to stay still. Typically, you would see this in nystagmus. Now, let's start with diplopia. Diplopia is a fairly common presenting complaint for neurologists, ophthalmologists, and the neuro-ophthalmologist. The first aspect in the management of diplopia is to differentiate between monocular diplopia and binocular diplopia. Now, monocular diplopia is when the double vision persists even after covering one eye. And that is never a neurological issue. It's almost always an ophthalmic problem, which means the patient will then have to be assessed by an eye care provider to identify what's causing it. And again, refractive error, cataracts, opacities, they can do it. Now, if the patient is able to see single vision by covering one eye at a time, that's binocular diplopia. Now, in patients with binocular diplopia in the very early stages of the disease, the standard treatment regimen is just monocular occlusion. Cover one eye, the diplopia goes away, and then give it time to improve on its own. So, this is what we would typically do in a patient with, say, acute sixth nerve palsy or fourth nerve palsy or third nerve palsy, maybe expect spontaneous improvement in a few months. Now if the double vision does not improve and persists long term, then the neuro-ophthalmologist or the ophthalmologist will monitor the amount of deviation to see if it fluctuates or if it stays the same. So, what are the treatment options that we have in a patient who absolutely refuses any intervention or is not a candidate for any intervention? Monocular occlusion still remains the viable option. Now, patients who have stable ocular deviation can benefit from using prisms in their glasses, or they can be sent to a surgeon to have a strabismus surgery that can realign their eyes. So, again, a broad answer, but there are options available that we can use. Dr Grouse: Thank you for that overview. I think that's just really helpful to keep in mind as we're working with these patients and thinking about what their options are. And then finally, I wanted to touch on patients with higher-order vision processing and attention difficulties. What are some strategies for them? Dr Kedar: These are frankly the most difficult patients that I get to manage in my clinic, simply because there is no effective therapies for managing them. In fact, I think neurologists are far better at this than ophthalmologists or even neuro-ophthalmologists. In patients with attentional disorders, everything boils down to the underlying cause, whether you can treat it or whether it is a slowly progressive, you know, condition, such as from neurodegenerative diseases. And that tailors our goals towards therapy. The primary goal is for safety. A lot of these patients who have visual disturbances from vision processing or attention, they are at accident and fall risk. They have problems with social interactions. And, importantly, there is a gap of understanding of what's going on, not just from their side but also from the family's side. So, I tend to approach these patients from a safety perspective and social interaction perspective. Now, I have a table listed in the manuscript which will go into details of what the specific things are. But in a nutshell, if your patient has neglect in a specific part of the visual field, they have accident risk on that side. Simple things like walking through a doorway, they can hurt their shoulders or their knees when they bang into the wall on that side because they are unable to judge what's on the other side. Another example would be a patient who has simultanagnosia or a downgaze policy, such as from progressive super nuclear policy. They are unable to look down fast enough, or they are simply unable to look down and appreciate things that are on the floor, and so they can trip and fall. Walking downstairs is also not a huge risk because they are unable to judge distances as they walk down. A lot of what we see in these patients are things that we have to advise occupational therapists and help them improve these safety parameters at home. Another thing that we often forget is patients can inadvertently cause a social incident when they tend to ignore people on their affected side. So, if there is a family gathering, they tend to consistently ignore a group of people who are sitting on the affected side as opposed to the other side. And I've had more than a few patients who've come and said that, I may have offended some of my friends and family. In those instances, it's always helpful when they are in clinic to demonstrate to the family how this can be awkward and how this can be mitigated. So, having everybody sit on one side is a useful strategy. Advise your family and friends before a gathering that, hey, this may happen. And it is not because it is deliberate, but it's because of the medical condition. And that goes a lot, you know, further in helping our patients come out of social isolation because they are also afraid of offending people, you know. And they can also participate socially, and it can overall improve their quality of life. Dr Grouse: That's a really helpful tip, and something I'll keep in mind with my patients with neglect and visual field cuts. Thank you so much for coming to talk with us today. Your article has been so helpful, and I urge everybody listening today to take a look. Dr Kedar: Thank you, Katie. It was wonderful talking to you. Dr Grouse: I've been interviewing Dr Sachin Kedar about his article on symptomatic treatment of neuro-ophthalmic visual disturbances, which appears in the most recent issue of Continuum on neuro-ophthalmology. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Tyler and Matt sit down with Jacob Perry of Superior Upland to talk life as a full-time upland guide in Michigan's Upper Peninsula. From building a guiding business with seven pointing dogs to why Gordon Setters stole his heart, Jake covers everything: bird habitat, client stories, gear advice, dog training philosophy, and the joy of sharing the woods with first-timers. Learn more about your ad choices. Visit megaphone.fm/adchoices

This week, we kick off with a bit of music, a bit of Britney and Biebs, and the fashion comeback NOBODY wants. Mel’s torn trying to protect her daughter from dickheads in cars, and we share the stuff we’ve had piffed at us from them. One of us also thinks they’ve come up with the best new slogan for Vic numbers plates, and the other is not convinced. Enjoy! Fancy supporting us on Patreon? Find out more here. Follow us and get in touch on Instagram here. Follow us on Facebook here.See omnystudio.com/listener for privacy information.

In this episode of The Birdshot Podcast, host Nick Larson talks with Logan Clark, a graduate researcher, about his extensive study on dusky grouse migrations and behavior. They discuss the challenges and innovations in monitoring wildlife, including the use of autonomous recording units (ARUs) and GPS tracking. Logan shares insights from his fieldwork, the modeling techniques applied for abundance estimation, and the future directions for dusky grouse research. 02:08 Pheasant Fest Experience 02:45 Poster Session and Networking 09:02 Research and Monitoring Techniques 37:40 Microphone vs. Human Detection 39:26 Challenges in Grouse Detection 40:07 Occupancy and Abundance Estimates 42:33 Machine Learning in Bird Detection 44:44 Developing Detection Models 52:50 Unexpected Discoveries 55:47 GPS Tracking and Grouse Movements 01:03:44 Future Research Directions 01:12:12 Career Aspirations and Challenges SUPPORT | patreon.com/birdshot Follow us | @birdshot.podcast Use Promo Code | BSP20 to save 20% with onX Hunt Use Promo Code | BS10 to save 10% on Trulock Chokes The Birdshot Podcast is Presented By: onX Hunt, Final Rise and Upland Gun Company Learn more about your ad choices. Visit megaphone.fm/adchoices

Fluent Fiction - Dutch: Mystery Unveiled: The Return of the Rare Black Grouse Find the full episode transcript, vocabulary words, and more:fluentfiction.com/nl/episode/2025-04-02-22-34-01-nl Story Transcript:Nl: In het hart van de Nederlandse platteland, te midden van kleurrijke velden tulpen en molens, speelt zich een vreemd verhaal af.En: In the heart of the Nederlandse countryside, amidst colorful fields of tulips and windmills, a strange story unfolds.Nl: Elke avond, bij zonsondergang, verschijnt er een eigenaardige schaduw langs de rand van het tulpenveld.En: Every evening at sunset, an unusual shadow appears along the edge of the tulip field.Nl: De dorpsbewoners fluisteren erover, verbaasd en nieuwsgierig.En: The villagers whisper about it, both amazed and curious.Nl: Maar niemand durft dichterbij te komen.En: But no one dares to come closer.Nl: Bram, een nuchtere boer en kind van het platteland, hoort de verhalen.En: Bram, a down-to-earth farmer and child of the countryside, hears the stories.Nl: Hij gelooft niet in bijgeloof, maar iets in dit mysterie prikkelt zijn belangstelling.En: He does not believe in superstition, but something about this mystery piques his interest.Nl: Hij wil weten wat er aan de hand is.En: He wants to know what is going on.Nl: "Het is vast iets gewoons," denkt hij bij zichzelf.En: "It's probably something ordinary," he thinks to himself.Nl: Maar zijn nieuwsgierigheid wint het, en hij besluit de schaduw nader te onderzoeken.En: But his curiosity gets the better of him, and he decides to investigate the shadow further.Nl: Sanne daarentegen is een slimme botanist uit Amsterdam.En: Sanne, on the other hand, is a clever botanist from Amsterdam.Nl: Ze bezoekt het dorp om de schoonheid van de bloeiende tulpen te bestuderen.En: She visits the village to study the beauty of the blooming tulips.Nl: Maar de verhalen over de schaduw trekken ook haar aandacht.En: But the stories about the shadow also capture her attention.Nl: Sanne ziet het als een kans om iets nieuws te ontdekken en zoekt naar wetenschappelijk bewijs.En: Sanne sees it as an opportunity to discover something new and seeks scientific evidence.Nl: Bram en Sanne besluiten samen te werken, ondanks hun verschillende benaderingen.En: Bram and Sanne decide to work together, despite their different approaches.Nl: Bram is op zoek naar eenvoudige verklaringen.En: Bram is searching for simple explanations.Nl: Misschien een kapotte windmolen of een oude boom, denkt hij.En: Maybe a broken windmill or an old tree, he thinks.Nl: Sanne heeft haar gereedschap bij zich en meet veranderingen in de omgeving.En: Sanne has her tools with her and measures changes in the environment.Nl: Ze zijn het niet altijd eens, maar ze zijn vastbesloten de waarheid te vinden.En: They do not always agree, but they are determined to find the truth.Nl: Op een avond gaat Bram naar het veld.En: One evening, Bram goes to the field.Nl: Sanne volgt met haar apparaten.En: Sanne follows with her equipment.Nl: De lucht kleurt roze en oranje terwijl de zon zakt achter de horizon.En: The sky turns pink and orange as the sun sets behind the horizon.Nl: De schaduw verschijnt, groter en scherper dan ooit.En: The shadow appears, larger and sharper than ever.Nl: Het heeft de vorm van een vogel, maar niet zomaar een vogel.En: It has the shape of a bird, but not just any bird.Nl: Bram herkent de contouren, iets wat hij nooit had gedacht opnieuw te zien.En: Bram recognizes the contours, something he never thought he would see again.Nl: "Een korhoen," mompelt hij verbaasd.En: "A black grouse," he murmurs, astonished.Nl: Een zeldzame vogel die hier al jaren niet is gezien.En: A rare bird that has not been seen here for years.Nl: Sanne kijkt op en glimlacht.En: Sanne looks up and smiles.Nl: "We moeten het vastleggen!" Samen zetten ze hun onderzoek voort.En: "We must document it!" Together, they continue their research.Nl: Bram's kennis van de omgeving en Sanne's wetenschap komen samen.En: Bram's knowledge of the environment and Sanne's science come together.Nl: Ze maken foto's, notities, en meten alles wat ze kunnen.En: They take photos, make notes, and measure everything they can.Nl: Uiteindelijk, met bewijs in handen, informeren Bram en Sanne de lokale gemeenschap.En: Eventually, with evidence in hand, Bram and Sanne inform the local community.Nl: De mensen zijn opgetogen, de vogels zijn weer terug.En: The people are thrilled; the birds have returned.Nl: Bram leert om de mysteries van het leven te omarmen en Sanne ziet de waarde in van volkswijsheid.En: Bram learns to embrace the mysteries of life, and Sanne sees the value in folk wisdom.Nl: Ze beseffen dat ze een bijzonder moment hebben gedeeld. Een moment waar wetenschap en intuïtie elkaar ontmoetten, in de volle pracht van de Nederlandse lente.En: They realize they have shared a special moment—a moment where science and intuition met, in the full splendor of the Nederlandse spring.Nl: Zo sluiten ze hun avontuur af, met een hernieuwd respect voor zowel het onbekende als het vertrouwde.En: And so they conclude their adventure, with a renewed respect for both the unknown and the familiar.Nl: En elk jaar met Pasen kijken ze samen naar de velden, hopend op nog een glimp van de zeldzame korhoen, daar waar tulpen en verhalen bloeien.En: And every year at Easter, they watch the fields together, hoping for another glimpse of the rare black grouse, where tulips and stories bloom. Vocabulary Words:heart: hartamidst: te midden vancountryside: plattelandunusual: eigenaardigewhisper: fluisterenamazed: verbaasdcurious: nieuwsgierigdare: durftsuperstition: bijgeloofmystery: mysteriepique: prikkeltbotanist: botanistblooming: bloeiendeapproaches: benaderingendetermined: vastbeslotenhorizon: horizoncontours: contourenastonished: verbaasdgrouse: korhoenmurmurs: mompeltdocument: vastleggenenvironment: omgevingnote: notitiesthrilled: opgetogenembrace: omarmenwisdom: wijsheidintuition: intuïtiesplendor: prachtrenewed: hernieuwdglimpse: glimp

Summary: In this episode, Justin Townsend and Adam Berkelmans discuss the evolving landscape of hunting in North America, focusing on the rise of food-focused hunters and urban deer hunting. They are joined by AJ DeRosa, who shares his insights on urban deer hunting, the importance of food in hunting culture, and the unique culinary experiences that come with wild game. The conversation explores the challenges and opportunities in modern hunting, conservation policies, and the stories that connect hunters and non-hunters alike. In this conversation, the speakers delve into various topics related to hunting, cooking, and conservation. They discuss the value of bear meat and fat, innovative cooking techniques using indigenous ingredients, and the underappreciated culinary potential of octopus. The conversation transitions into the origins and growth of Project Upland, emphasizing its authenticity and commitment to ethical hunting practices. The speakers also address the challenges facing hunting and conservation today, including the need for a more responsible approach to wildlife management and the importance of acknowledging the impact of lead in hunting. In this conversation, AJ discusses the evolving landscape of hunting, emphasizing the need for the community to embrace scientific truths and adapt to changing practices. He highlights the curiosity of younger hunters, the challenges of recruitment through the R3 program, and the integral role of food in hunting culture. AJ also delves into the political aspects of conservation, arguing that the narrative surrounding hunting has been skewed by partisan politics. He advocates for diplomacy and collaboration among hunters and conservationists to ensure the future of hunting rights and wildlife management. - Leave a Review of the Podcast - Buy our Wild Fish and Game Spices The Art of Venison Sausage Making Guest: AJ DeRosa Instagram Project Upland Instagram Project Upland Website Takeaways: Wild food is reshaping the way we think about hunting. Grouse hunting offers a unique culinary experience compared to big game hunting. Learning to handle wild game properly is essential for quality cooking. Diversity in wild game offers a rich culinary experience. Bear fat is highly valued for its culinary uses. Innovative cooking can elevate traditional ingredients. Octopus is an underappreciated delicacy that deserves more attention. Project Upland originated from a desire to spend more time hunting. Younger hunters are more curious and engaged with ecological issues. The narrative around hunting needs to be reframed. Community engagement is crucial for the future of hunting. Chapters: 00:00 Introduction to Wild Food and Hunting Culture 05:31 AJ DeRosa: Background and Urban Deer Hunting 09:31 The Evolution of Hunting Techniques 22:11 The Role of Food in Hunting 28:43 Culinary Experiences with Wild Game 29:10 The Value of Bear Meat and Fat 31:05 Innovative Cooking with Indigenous Ingredients 33:05 Exploring the Culinary Potential of Octopus 33:59 The Birth of Project Upland 38:54 The Authenticity of Project Upland 44:59 The Ethics of Hunting and Conservation 51:59 The Future of Hunting and Conservation Challenges 55:32 Embracing Change in Hunting Practices 58:11 The New Generation of Hunters 01:00:19 R3 Recruitment and Its Challenges 01:04:26 The Role of Food in Hunting Culture 01:07:03 Politics, Conservation, and Public Perception 01:12:39 The Class War in Hunting Rights 01:15:45 Building Bridges: Diplomacy in Conservation 01:20:34 The Future of Hunting and Food Culture Keywords: Wild food, hunting culture, urban deer hunting, conservation policy, food-focused hunters, hunting techniques, culinary experiences, wildlife, food culture, hunting, conservation, food culture, recruitment, public perception, politics, wildlife management, new generation hunters, R3 program, community engagement Learn more about your ad choices. Visit megaphone.fm/adchoices

This week we head to the highlands to meet the capercaillie, a glorious grouse in need of help. In the news, we look at how all areas of modern science are contributing to a wider understanding of how dinosaurs lived. All this and more. The cupboard is open, come on in!

Dennis and I catch up on some of the events and offerings at Aspen Thicket. We also go over a number of events hosted by Uncle Grouse this coming off season for the newcomer and experienced hunter alike.

In This Hour:--  Family stories continue around a Montgomery Ward pump action 22.--  Hunting grouse and quail --  Make sure you check the expiration date on your pepper sprayGun Talk 03.23.25 After Show

Grouse for dinner

EEG is the single most useful ancillary test to support the clinical diagnosis of epilepsy, but if used incorrectly it can lead to misdiagnosis and long-term mental and physical health sequelae. Its application requires proper understanding of its limitations and variability of testing results. In this episode, Katie Grouse, MD, FAAN, speaks with Daniel Weber, DO, author of the article “EEG in Epilepsy,” in the Continuum® February 2025 Epilepsy issue. Dr. Grouse is a Continuum® Audio interviewer and a clinical assistant professor at the University of California San Francisco in San Francisco, California. Dr. Weber is the director of adult epilepsy and vice chair of clinical affairs at the St. Louis University in St. Louis, Missouri. Additional Resources Read the article: EEG in Epilepsy Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Guest: @drdanielweber Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Grouse: This is Dr Katie Grouse. Today, I'm interviewing Dr Daniel Weber about his article on EEG and epilepsy, which appears in the February 2025 Continuum issue on epilepsy. Welcome to the podcast and please introduce yourself to our audience. Dr Weber: Hi, thanks for having me. My name is Dan Weber and I'm an epileptologist at Saint Louis University. I direct the adult epilepsy program here and also serve as the vice chair for Clinical Affairs. Been my pleasure to work on this article. Dr Grouse: I'm so happy to have you today. I read your article. I found it to be incredibly useful as someone who often orders EEG in the general neurology clinic. So, I wanted to start with asking, what is the most clinically relevant message or takeaway from your article that you'd really like neurologists to know?  Dr Weber: Yes, when I was asked to write this article, I looked back at the previous Continuum on epilepsy and just the general literature. And there's a lot of good articles and books out there on EEG and epilepsy and sort of giving you a primer on what you might see and how to interpret it. So, we wanted to try to go a slightly different direction. This article gives you some of that gives you the background of EEG and some of the basic things that you may see, but the real thrust of it is more about the limitations of EEG in the clinical picture of epilepsy and common things you might avoid. There are some things that we get hammered into our brains in training that aren't always true and there's plenty of examples in the literature to review, and this article sort of tries to encapsulate as many of those as possible in a digestible format. The main takeaway would be that EEG is an extremely helpful tool in the diagnosis of epilepsy, is the best tool we have to help supplement your clinical acumen. But it does not make the diagnosis of epilepsy. And there are certain circumstances when it may not be as helpful as you may have been led to believe in residency. Dr Grouse: Maybe not the most comforting of messages, but certainly an important one, very important to learn more about this. So, we appreciate that. Can you tell us your decision-making process when deciding whether to order a routine EEG, an extended EEG, prolonged ambulatory EEG, or inpatient video EEG? Dr Weber: Sure. So, it's a multi-part question because each one, I think, has a different clinical scenario. In the current state, our best data for estimating risk of recurrence after an initial seizure comes with routine EEG abnormalities. So, often I will order routine EEGs in those scenarios. So new patient presentation, new patients coming in with an initial seizure who want to know what's their risk of recurrence. So, risk stratification, I use a lot of routine EEG for, often sleep deprived if possible to increase the sensitivity. If you'd like, the extended EEG does offer higher sensitivity, or you can repeat the routine EEG if the first routine EEG is nonconclusive. For generally extended EEGs, I tend to order them in my practice if patients have come to see me with a suspected diagnosis of epilepsy but haven't yet had any electrographic confirmation. Maybe they've already had routine EEGs done in the past, so we'll try to obtain just a little more data. The longer-term EEGs I tend to use in different clinical scenarios, in patients usually who already have established diagnosis or people who have become refractory and we haven't yet confirmed their diagnosis. I tend to do inpatient EEGs in those situations. Ambulatory EEGs I do more when there are certain characteristics of the patient or the patient 's presentation that may not fit well on the inpatient side. Patients who are reliant on substances who can't use while they're inpatient and may have withdrawal effects complicating the stay. Or people who have a strong activation component to their epilepsy where activity really draws it out, certain activities that they do at home that they might not do during the inpatient stay. Those are the sorts of people I'll do ambulatory EEGs on. There are a couple other scenarios as well that come up less commonly, but everything has its own little niche. Dr Grouse: That's a really helpful review as we sort of think about which way we want to go as we're working up our patients in the inventory setting. Can you tell me a little more about the difference between sensitivity of, for instance, doing maybe two routine EEGS versus prolonged ambulatory EEG? Dr Weber: Generally speaking, the longer you're recording someone's brain waves, the higher the sensitivity is going to be. So routine EEG is twenty to forty minutes at most places. One of those gives you a certain sensitivity. More of them will give you more sensitivity. And there was a recent study highlighted in the article that compared routine EEGs to initial multi-day ambulatory EEG, and the ambulatory EEG obviously, as would be expected, has a higher sensitivity than either of the routines. So, there may be some cases with that initial evaluation where an ambulatory EEG may be held and we get into that in more detail in the article. But with the caveat, a lot of this article is about limitations, and the data that we have to talk about increased risk of recurrence was based off seeing epileptic form discharges on routine EEG. So you could hypothesize that if you only have one epileptic form discharge in three days on an ambulatory EEG, that may not carry the same recurrent significance as catching one on a twenty minute EEG. But we don't have that knowledge. Dr Grouse: Getting a little bit more into what you mentioned about the limitations, when is the scalp EEG less useful or limited in the evaluation of epilepsy? Dr Weber: So, one thing I see a lot in my residence at here and other places where I've worked is, I get them very excited about EEG and they may order it a bit too much. So, if patients have a known, established diagnosis of epilepsy, electrographically confirmed, and they come in with a breakthrough seizure and they're back to their baseline, there's really not a strong reason to get an EEG. We often seem to in the emergency department as part of our evaluation, but we already know what happened to the patient. The patient's not doing poorly right now, so the EEG is not going to give you any additional information. Just like really any test, you should think, what are the possible outcomes of this test and how would those outcomes alter the care of this patient? And if no outcome is going to affect the care of the patient or give you any additional diagnostic information, then probably don't need to be doing that test. Dr Grouse: This is probably a good segue into asking, what is an area of confusion or common pitfalls that you've seen in the clinical application of EEG and epilepsy? Dr Weber: So, a lot of times on the inpatient service, we'll get longer-term EEGs for patients who are having spells that are occurrent while they're in the ICU or other places or altered in some way, encephalopathic. And these patients will have their spell, and in my report, I'll say that there is not any electrographic correlate. So, there's no EEG finding that goes along with the movement that they're doing that's concerning for a seizure. And that doesn't always mean that it's not an epileptic seizure. An EEG is not a one-hundred-percent tool. Epilepsy and seizures are a clinical diagnosis. The EEG is a helpful tool to guide that diagnosis, but it is not foolproof, so you need to take the whole clinical picture into account. Particularly focal seizures without impaired awareness often can be electrographically silent on surface EEG. If you see something that looks clinically like a seizure but doesn't show up on the EEG, there are circumstances that they get to in the paper a little bit where that can still be an epileptic seizure. And you just have to be aware of the limitations of the tests that you're ordering and always fall back on the clinical skills that you've learned. Dr Grouse: Are there any tips or tricks you can suggest to improve the clinical utility of EEG for diagnosis of epilepsy? And also thinking about the example you just gave, but maybe other cases as well? Dr Weber: Again, definitely need to incorporate EEG as part of a larger picture. The video component of EEG is incredibly helpful. You can't interpret EEG in isolation. Regardless of what the EEG shows, you can't make a diagnosis of epilepsy, but you certainly can be very suspicious of one. So, in those cases where you have a high suspicion for an epileptic seizure and the EEG has not given you any confirmatory evidence, it's really helpful to rely on any clinical expertise that you have access to. So, people who have seen lots of seizures may be helpful in that situation. Getting good recordings, good data to prove yourself one way or the other is helpful and continuing to evaluate. So usually, as I said, focal seizures that don't show up well on the EEG. People who have focal seizures will often have larger seizures if left untreated. So, you can try to admit them to an epilepsy monitoring unit where we try to provoke seizures and try to provoke a larger seizure to help confirm that diagnosis. Dr Grouse: This kind of gets into what we've already reviewed to some degree, but what is the easiest mistake to make (and hopefully avoid) when using EEG to diagnose epilepsy or make other treatment decisions? Dr Weber: I think the easiest, most common mistake I see is overreliance on the test. There's a lot of subjectivity to the interpretation of this test. There are a lot of studies out there on interrater reliability for epilepsy and intrarater reliability for epilepsy. We continue to try to make the findings more objective and get more quantified. The articles talk about our six criteria for epileptiform discharges and have reference to where that came from and the sorts of specificity that each of those criteria lead to. Just because an EEG report has said something, that does not diagnose or negate a clinical diagnosis of epilepsy. It is common for folks with non-epileptic seizures to have a history of reported epileptic form discharges on their EEG. Again, because there is some subjectivity to the test, some abnormal-looking normal variants will pop up and get interpreted as epileptiform discharges. It's important to review the whole patient, as much of the data as you can, and make the best clinical judgment you can of the overall case. Dr Grouse: What is quantitative EEG and how can it be clinically useful? Dr Weber: Now that most EEG is obtained digitally through the use of computer software, we have been able to employ computers to do a lot of the work for us. There are many different ways of looking at the EEG data, but it's all frequency bands over time. The quantitative EEG goal is really to simplify and condense what you're seeing on your normal EEG page into a more digestible format. Lets you look at a larger amount of data faster, which becomes more and more important as we're doing more of these long-term recordings, particularly in the intensive care unit. Quantitative EEG can help you assess a lot of data at a snapshot and get a general sense of what's going on with the patient over the past several hours. It does require some extra training to become familiar with it, but it's training that can be done at all levels. Again, it can help you see more, faster. Obviously, like everything, it has its own limitations. Sometimes the sensitivity and specificity may be a little off from the raw data review, and you should always go back to the raw data anytime there are questions. But it can be helpful to make things faster. Dr Grouse: Do you think you could give me a hypothetical example of a case where this would be something really nice to have?  Dr Weber: The most common example is folks with repetitive seizures in the ICU. If you're just looking at the raw data, you will get a sense of how often the seizures are happening. But if you look at the quantitative data, it sort of compresses that all down to a much smaller snapshot. So you can see much more readily, yes, these are how many seizures were happening. And here's where we gave our intervention; and look, there are fewer seizures after that intervention. So, it can help you assess response to treatment, help you assess just overall volume of seizures in a much more condensed fashion, and you can get through it much faster with the appropriate training. Dr Grouse: Can you tell us about any new developments in EEG that are on the horizon we should be aware of?  Dr Weber: Yeah. So, I think my two favorites, which I highlight in the article, are longer-term recordings---so, there's some companies that are working on subcutaneous EEG. So, implanted EEG electrodes that can stay in your body for the short, long term on the order of year or years and constantly send some EEG data. Obviously, it's not a full montage in most of those cases, but some EEG data that can help you assess long-term trends in epilepsy and long-term response to therapies. I think that's going to be really cool. I think it's very exciting and I think it'll change how we do clinical trials in the future. I think we'll be able to rely less on seizure diaries from folks and more on objective seizure data for patients who have these implanted. But with that will come an ever-increasing amount of data to be reviewed, which leads into the other exciting future trend is AI in the use of interpretations. AI is becoming more and more advanced and there are very exciting articles out on how good AI is getting at interpreting our EEGs. I think soon, in the very near future, the AI platforms will be able to dramatically reduce the amount of time it takes the experts to review an EEG. They'll be able to do a lot of the screening for us and then we can go back, just like I was talking about the quantitative EEG, go back and review segments of the raw data rather than having to review every page of every file, which is quite time consuming. Dr Grouse: Wow, that's really exciting. It certainly does seem like AI is making breakthroughs in just about every area of how we touch the practice of medicine. Exciting to hear that EEG is no exception. Dr Weber: Yeah, I'm fully excited. I think it's going to revolutionize what we're doing and also just greatly expand people's ability to access that level of expertise that the AI will offer. Dr Grouse: I wanted to transition to talking a little bit more about you and your career in neurology. How did you become interested in this area of neurology to begin with? Dr Weber: Yeah, it's sort of a roundabout fashion. So, I started out planning to be a neurointerventionalist, and then I realized that I didn't want that sort of call. For a hot minute in my PGI 3 year. I was planning to be a neuro-ICU doctor. I think that's largely because medicine is all I had been exposed to at that point and the ICU seemed like a very comfortable place. Then as I transitioned into PGI 3 we started doing more electives and outpatient rotations in my residency. And then I was planning on being a movement disorder specialist or an epileptologist, couldn't make up my mind for the longest time. And then I started to like EEG more than I liked watching videos. So, tilted myself towards epilepsy and haven't looked back.  Dr Grouse: Well, I really appreciated you coming to talk with us today about your article. I can't recommend it enough to anyone out there, whoever treats patients with epilepsy or orders the EEGs, I just think it was just incredibly useful. And it was such a pleasure to have you. Dr Weber: Thank you very much for having me, Katie.  Dr Grouse: Again, today I've been interviewing Dr Daniel Weber about his article on EEG and epilepsy, which appears in the most recent issue of Continuum on Epilepsy. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.  

Jake Faas of True Loyalty Dog Training joins the show this week to share how he fell in love with dogs doing bite sports and training working dogs and then through marriage came to upland hunting and owning French Brittanies. Jake is an experience bite dog trainer and decoy, but never hunted until his father-in-law told him he wasn't a member of the family until he killed a grouse. After that the rest was history.This episode contains a ton of gems for the avid bird dogger and trainer.Enjoy!This episode is brought to you by Ugly Dog Hunting Co. Shop now at UglyDogHunting.com.Music used under Creative Commons -Two Step Daisy Duke by Mr. Smith is licensed under an Attribution 4.0 International License.

Recent progress in neurogenetics and molecular pathology has improved our understanding of the complex pathogenetic changes associated with neurodegenerative dementias. In this episode, Katie Grouse, MD, FAAN, speaks with Sonja W. Scholz, MD, PhD, FAAN, an author of the article “Genetics and Neuropathology of Neurodegenerative Dementias,” in the Continuum® December 2024 Dementia issue. Dr. Grouse is a Continuum® Audio interviewer and a clinical assistant professor at the University of California San Francisco in San Francisco, California. Dr. Scholz is a senior investigator at the National Institutes of Health in Bethesda, Maryland and an adjunct professor of neurology at Johns Hopkins University in Baltimore, Maryland. Additional Resources Read the article: Genetics and Neuropathology of Neurodegenerative Dementias Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Full episode transcript available here:  Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Grouse: This is Dr Katie Grouse. Today I'm interviewing Dr Sonia Scholz about her article on genetics and neuropathy of neurodegenerative dementias, which appears in the December 2024 Continuum issue on dementia. Welcome to the podcast, and please introduce yourself to our audience.  Dr Scholz: Thank you so much for inviting me. My name is Sonia Scholz. I'm a neurologist working at the National Institutes of Health. My main focus of research and clinical work are neurodegenerative diseases, and I have a particular interest in using modern genomic tools to understand these diseases and potentially leverage it for new translational applications. Dr Grouse: Sonia, we're really excited to have you today and thanks for joining us.  Dr Scholz: I'm pleased to be here.  Dr Grouse: I'd like to start by asking what you think is the most important message or takeaway point from your article? Dr Scholz: So, this is an article that really captures a very broad and exciting field. So, one thing I wanted to really highlight is that there's a lot of heterogeneity, clinical, pathological, molecular heterogeneity in age-related neurodegenerative dementia syndromes. Our article was really aimed at providing a bird's eye view of the pertinent pathological characteristics, but also important genetic advances and insights and how we can leverage that, particularly in the new physician medicine era, hopefully come up with better treatments and better ways to counsel our patients.  Dr Grouse: What do you think is the most challenging aspect of understanding the genetics and neuropathologic basis of neurodegenerative dementias?  Dr. Scholz: That's a good question. There're many big and challenging questions, but I think one of the things we struggle the most with is really the heterogeneity. I see patients with one and the same Mendelian form of dementia. One patient is in their forties another patient is in their eighties, and the clinical manifestations can be very different from one patient to another. There's a lot of heterogeneity, also, on the pathological level. Not every patient has exactly the same distribution. And so, we're starting to slowly define what the underlying causes are, but it's still quite baffling and quite challenging to put them together and understand them. Dr Grouse: Do you feel that the genome-wide association studies has helped our understanding of these diseases, specifically the heterogeneity? And if so how?  Dr Scholz: That's a great question, but you're talking to a geneticist here. And I definitely would say genome-wide association studies have helped us a lot in identifying what the underlying disease pathways are and what the relationships between neurodegenerative disease entities are. It really also gave us a better understanding of apparently sporadic diseases where genetic factors are still playing a role. And we can leverage that type of knowledge increasingly to highlight high-risk groups, but also, we can increasingly use it to stratify patients for clinical trials, for example. And that's really exciting and there's still a lot of knowledge that we have to garner very quickly, especially in the non-Alzheimer dementia space.  Dr Grouse: You've mentioned, of course, the heterogeneity and these syndromes. And in your article, you go into a lot of the issue of the significant crossover between the genetic links and the neuropathological findings for the various types of neurodegenerative dementias. Do you think that this crossover has been more of a help or a hindrance in better understanding these diseases? Dr Scholz: Yeah, it can be a little bit, you know, challenging to wrap one 's mind around it. But by and large, I think it's actually good news because it highlights that there is a shared biology between many of the neurodegenerative disease entities. And by figuring out which the pathways are that are very often involved, we can prioritize certain targets for therapy development. But we can also be smarter about how we developed treatments. We could repurpose a drug that has been developed for Alzheimer's disease very easily for Lewy body dementia because we increasingly understand the overlap. And we can also leverage new clinical trials design, like basket trials. This is something that has been really transformative in the oncology sphere and now, increasingly, neurodegeneration. We're trying to apply that kind of thinking as well to our patient populations. Dr Grouse: What do you think our listeners will find to be most surprising when they read the article? Dr Scholz: We often present these diseases in our textbooks as these black-and-white entities, but the reality is that there's a lot of overlap. And we also see that co-pathologies are actually the norm and not the exception, and a lot of the molecular risk factors are shared. It's not really surprising. And I think that overlap and crosstalk between the various diseases is something that's a little bit strange to think about, but it actually makes increasingly sense now that we see the genetic risk profiles coming up. Dr Grouse: In reading your article, I was really struck by how many, or how much the prior studies have been lacking in inclusion of different ethno-racial backgrounds in the patients who've been studied. How can this be improved going forward?  Dr Scholz: Yeah, thank you. That's a really important and crucial question, and I think it really takes the collective effort of everybody in the healthcare research community to improve upon that. We need to talk to our patients about genetic testing, about brain donation programs, about referrals to clinical trials, and don't feel shy about reaching out to our colleagues and academic centers, even if you don't have the resources in a smaller institution. We also not only need to engage with the communities, we also need to build up a healthcare research community that has representatives from these various communities. So, it's really a collective effort that we build up and are proactive about building a more equitable healthcare system and research system that works for all of us and that really is going to provide us with the precision medicines that work for everybody. Dr Grouse: What do you think is the biggest debate or controversy related to the genetics and neuropathology of neurodegenerative dementias?  Dr Scholz: Yeah, there are loads of interesting debates, but I think in my field, in particular in the genetics is what to do with risk variance. What is it that I actually communicate to the patient? Obviously, I can learn a lot on the bench and I think I can use a lot of the genetic risk factors for molecular modeling, etc. But to which extent should I share that information? Because genetic information is something that we cannot alter and many of the risk factors are actually mild, that they may never result in disease. And so, communicating risk with patients is something that's very challenging and we used to just steer away from it. But now the discussion is starting to shift a little bit. You know, nowadays we are starting to offer, for example, testing for the APOE4 allele in individuals who are considering antiamyloid therapies. And this really, this is precision medicine in his earliest days because it allows us to stratify patients into those that are high-risk versus low-risk and those that need more frequent follow-up or may be advised not to pursue this treatment. And we're probably going to see more of those discussions and the ethics around it. And it's even harder in an aged population where you know, you may never manifest any of the symptoms despite carrying a lot of these risk deals. Dr Grouse: You mentioned, you know, that testing, APOE4 testing for certain populations when deciding to do the antiamyloid immunotherapies. Apart from that, which I think is a really good example of where genetic testing makes sense, what other scenarios do you think it makes sense at this point in time to recommend genetic testing for symptomatic patients who are concerned about neurodegenerative dementias? Dr Scholz: Yeah. So, I usually have a very frank discussion with patients in whom I suspect the genetic etiology. So those are individuals who have a strong family history, individuals from very early onset of the disease where genetic testing may allow us to establish a molecular diagnosis, individualize and refine our counseling, and potentially get them into targeted clinical trials that may be suitable for that. Those are always very nuanced discussions, but I usually start with those high-risk individuals. Increasingly patients are, even with the apparently sporadic forms, are asking me about it. And then I have a frank discussions about the pros and cons and offer it to the patients who really would like to pursue it.  Dr Grouse: That makes a lot of sense. What about in the case of patients who are asymptomatic but might have high risks because of, well, family members with certain types of neurodegenerative dementias? When would it make sense, if ever, to do genetic testing for them? Dr Scholz: Yeah, that's a that's a tough situation, to be honest. By and large, I would say I would like to understand what the motivation is to learn about the genetic status. If the motivation is something like family planning, future care planning, etc, then it may be a reasonable thing. But I also want to make it very clear upfront that knowing a genetic status, at least aside from APOE status, at least for now, doesn't actually change the clinical management. And I want to make sure patients understand if they are trying to lower their risk, knowing that genetic status is not going to lower their risk. There are other things, brain health habits, that are really important, that patients should double down on: avoiding vascular disease, avoiding traumatic brain injury, excessive alcohol use, etcetera. It's a discussion that really tries to understand the motivations behind the testing. But some patients are very frank and they want to have it. They may want to contribute to the research community, and so in those instances we may offer it, but I also really want to make them understand that knowing a genetic diagnosis may be acceptable to them, but family members who are related to them may not wish to know. And they can really cause a lot of psychological stress that extends beyond the individual. And then that's something to really consider before actually pursuing testing. Dr Grouse: I think that's a really good reminder, especially about how this can even affect people outside of the patient themselves. I think a lot of us don't even think about that. And certainly, our patients may not either. Taking it a step further, thinking about newly available biomarkers, imaging modalities, how should we incorporate the use of these for our patients when we're suspicious of things like Alzheimer's disease or dementia with the Lewy bodies? Dr Scholz: So by and large these biomarkers are used in in the research area, but we can, in a given patient where maybe the clinical presentation is somewhat atypical, we can use it to help with our diagnostic impression. It doesn't get rid of the clinical evaluation, but at least it gives us a little bit more certainty. Here are the you know, the molecular features, the abnormal amyloid tau deposits, for example, that we're there we're detecting supports diagnosis. May also sometimes help in patients where we suspect there could be even the co-pathology going on where we get a mixture of features, where we can counsel the patients and you know, detecting copathologies is something that is certainly challenging. We know that patients who have more pathologies on average are not doing as well as the ones who have relatively pure disease forms. But this is also an area of intense research and as long as it's used judiciously to help with the diagnostic compression, to reduce a diagnostic odyssey, I think there's a lot of potential there to improve the clinical evaluations nowadays. Dr Grouse: It is really exciting to see the options that are opening up as the years go by, which brings me to my next question. There is certainly, as we know, this new category of disease modifying therapies that are available in the form of the anti-amyloid immunotherapies. What else do you think's on the horizon for treatment and prevention, neurodegenerative dementias, going down the road five, ten, fifteen years down the line?  Dr Scholz: Yeah, I think we're entering the era of precision medicine already and we're, we're seeing it already with the anti-amyloid therapies. By and large, I think the standard of care is going to be a multidisciplinary individualized treatment plan that incorporates a more holistic view. It incorporates diet, lifestyle factors, symptomatic management, but also disease modification strategies and potentially even multitarget disease modifying strategies. I think there's a lot more work that we have to do, especially in in the non-Alzheimer's dementia field. But overall, we're becoming much better in refining our diagnostic impression and in treating some of the complications that arise in these very complex diseases.  Dr Grouse: I'm curious, with the future of dementia care and diagnosis being more of a precision medicine model, how do you think this will be possible in an aging population with already, I think, probably a limited access to neurologists even in current state? Dr Scholz: Yeah, this is- these are these are very challenging societal questions. Increasingly, you know, we can use modern technologies such as televisits for follow up, but also, you know, remote monitoring devices. We have to educate the next generation, we need more neurologists, we can't do it alone; but we also need to empower primary care doctors who are usually the first go-to person. And perhaps biomarker testing will become much more common even in the primary care setting. I think overall, you know, we can tackle it by educating the community, empowering participants in various clinical trials, and being flexible of embracing certain new technologies. Dr Grouse: Absolutely. I think that makes a lot of sense and hopefully this will be another call to arms to try to get the word out, get more access to neurology and more people interested and like you said, getting our other colleagues involved and being able to manage it as well.  Dr Scholz: Yeah.  Dr Grouse: I wanted to transition a little bit into learning more about you. How did you become interested in genetics of neurodegenerative dementias? Dr Scholz: Yeah, it's something, it's an interest that has grown gradually. I started out as a neuroscientist in in Austria, where I was fortunate to work with a group that was very strongly involved in Parkinson's disease care. And I was so thrilled to see patients, you know, treated with deep brain stimulation. But yet in the same clinic, I also saw the patients who were not eligible because they had atypical neurodegenerative diseases. And it's the realization that there is such a broad spectrum of diseases that we frankly don't understand very well, that we really need to work with, understand and hopefully develop the treatments with. That's really has resonated with me. And I've since then really built my entire career around it through different countries at the United Kingdom and the United States. And I'm very fortunate to work at the National Institutes of Health, where I can pursue a lot of these research passions and work with interesting patients and colleagues.  Dr Grouse: Well, I've learned a lot today, and I'm sure our listeners would agree. Thank you so much for joining us. It's really been a pleasure speaking with you.  Dr Scholz: Well, thank you so much for allowing me to contribute. And, you know, I hope the review article conveys a lot of the exciting developments in this really challenging field. But there's loads of hope that we will eventually get to the point to tackle these conditions.  Dr Grouse: I encourage all of our listeners to check out Dr Scholz 's article. It is a great overview of these conditions and the genetics and neuropathology underlining them. Again, thank you so much.  Dr Scholz: Thank you for having me. Dr Grouse: Again, today I've been interviewing Dr Sonia Scholz, whose article on genetics and neuropathology of neurodegenerative dementias appears in the most recent issue of Continuum on dementia. Be sure to check out Continuum audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/AudioCME. Thank you for listening to Continuum Audio.

During winter, the Greater Sage-Grouse is wholly reliant on its namesake species — sagebrush — for both shelter and for food. Scientists call this bird "sagebrush obligate," meaning it needs this plant to survive. In the spring, its diet shifts to insects and plants, as it gets ready for the most fantastic mating show in the west — the lekking season.More info and transcript at BirdNote.org. Want more BirdNote? Subscribe to our weekly newsletter. Sign up for BirdNote+ to get ad-free listening and other perks. BirdNote is a nonprofit. Your tax-deductible gift makes these shows possible. 

Vascular cognitive impairment is a common and often underrecognized contributor to cognitive impairment in older individuals, with heterogeneous etiologies requiring individualized treatment strategies.  In this episode, Katie Grouse, MD, FAAN speaks with Lisa C. Silbert, MD, MCR, FAAN, an author of the article “Vascular Cognitive Impairment,” in the Continuum December 2024 Dementia issue. Dr. Grouse is a Continuum® Audio interviewer and a clinical assistant professor at the University of California San Francisco in San Francisco, California. Dr. Silbert is is co-director at Oregon Alzheimer's Disease Research Center, a Gibbs Family Endowed professor of neurology, a professor of neurology at Oregon Health & Science University, a staff neurologist, director of Cognitive Care Clinic, and director of the Geriatric Neurology Fellowship Program at Portland Veterans Affairs Health Care System in Portland, Oregon. Additional Resources Read the article: Vascular Cognitive Impairment Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Full transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum Journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Grouse: This is Dr Katie Grouse. Today I'm interviewing Dr Lisa Silbert about her article on vascular cognitive impairment, which is part of the December 2024 Continuum issue on dementia. Welcome to the podcast and please introduce yourself to our audience.  Dr Silbert: Hi Katie. Thanks for having me here today. Like you mentioned, my name is Lisa Silbert. I am a behavioral neurologist at Oregon Health and Science University and my research focus is in the area of vascular contributions to cognitive impairment and dementia. Dr Grouse: It's such a pleasure to have you and I really enjoyed reading your article. Just incredibly relevant, I think, to most practicing general neurologists, and really to any subspecialty. I'd like to start by asking, what do you think is the main takeaway point of your article for our listeners?  Dr Silbert: Yeah. I think, you know, the field of vascular cognitive impairment has changed and evolved over the last several decades. And I would say the main take-home message is that vascular cognitive impairment or vascular dementia is no longer a diagnosis that is only considered in someone who's had acute decline following a clinical stroke. That we have to expand our awareness of vascular contributions to cognitive impairment and consider other forms of the disease that can cause a more subacute or slowly progressive form of cognitive impairment. And there are many, many forms of vascular cognitive impairment that present in a more slowly progressive manner. The other thing I would say as a major take-home message is that we know that cerebrovascular disease is a very common copathology with other forms of dementia and that it lowers one 's threshold for manifesting cognitive impairment in the context of multiple pathologies. And so, in this way, vascular cognitive impairment should be considered as a contributing and potentially modifiable factor in any dementia.  Dr Grouse: I found that last point just really, really fascinating. And also, you know, the reminder that a combination of pathologies are more common than any one. To your initial point, I'm actually curious, could you kind of outline for us how you approach diagnosing vascular cognitive impairment?  Dr Silbert: Yeah. So with everything in neurology, a lot of it comes down to the initial history taking. And so part of the work up always includes a very detailed history of the presentation of cognitive impairment. Any time there is an acute change in cognition, vascular contribution should be considered, particularly if it's in the context of a clinical stroke or some kind of event that might have lowered cerebral blood flow to the brain. And then having said that, I already mentioned there are many forms of vascular cognitive impairment that can mimic neurodegenerative disease in terms of its course. So being more slowly progressive. And so because of that neuroimaging, and in particular MRI, has become an extremely valuable tool in the workup of anyone who presents with cognitive impairment in order to evaluate contributions from cerebral vascular disease. And so, MRI is a really helpful tool when it comes to teasing out what may be contributing to a patient's clinical syndrome, as well as their other comorbid medical issues, including stroke risk factors and other kind of medical conditions that might contribute to reduce cerebral blood flow. Dr Grouse: I'd love to talk a little bit more about that. You know, as is often the case with neurologic disease associated with vascular pathology, the importance of prevention, you know, focusing on prevention of vascular diseases is so important. What are some things that we can make sure to focus on with our patients and, you know, particularly anything new to be aware of in counseling them? Dr Silbert: Yeah, I'm really glad you asked me that question because like I mentioned, you know, cerebral vascular disease is so common, it lowers one's threshold for cognitive impairment in the face of other age-related brain pathologies. And so, it's really important for all of us to focus on preserving our cognitive health, even starting in midlife. And so, there are a number of areas that I counsel my patients on when it comes to preserving cerebral health and maximizing cerebrovascular health. And so, these stem from the American Heart Association's Life's Essential 8 because we know that preserving cardiovascular health is likely going to also preserve cerebral vascular health. And so, some of the things that I'm very commonly discussing with my patients are controlling stroke risk factors such as blood pressure, blood sugars and cholesterol, maintaining a healthy weight, and then also working towards a lifestyle that includes a healthy diet, no smoking, regular exercise. And then new within the last couple years is also the recommendation that people get adequate sleep, which is something that hasn't been focused on previously. Dr Grouse: I was really interested in reading your article to learn about enlarged perivascular spaces and the role as a mediating factor in the interaction between through a vascular dysfunction and development and progression of neurodegenerative pathology. Can you elaborate on this further? Dr Silbert: So, this is an area that's still largely unknown in the field, and it's an area where there's a lot of emerging work being done. The short answer is, we really don't know with great certainty how it directly connects with accumulating Alzheimer's pathology. But there is some evidence to suggest that the perivascular space is involved in the clearance of toxic solutes from the brain, including Alzheimer's disease pathology. And so there's a lot of work looking at how potentially cerebrovascular risk factors might affect the clearance of those toxic solutes through the perivascular space, including pulse pressure changes that might occur with accumulating cerebrovascular disease and other potential contributors. But one thing I can say with more certainty is that the, you know, location of perivascular spaces is thought to help distinguish those who might have cognitive symptoms due to cerebrovascular disease versus due to cerebral amyloid angiopathy. Or I guess I should say location is helpful in terms of recognizing vascular contributions to cognitive impairment that's due to arteriolosclerosis versus that due to cerebral amyloid angiopathy. In so much that… when we see a lot of perivascular spaces in the basal ganglia in the subcortical structures, that is thought to be more associated with arteriolosclerosis and hypertension type related vascular cognitive impairment. Whereas when we see multiple perivascular spaces within the centrum semiovale, that tends to be more associated with cerebral amyloid angiopathy. Dr Grouse: That's so interesting. And on the topic ofcerebral amyloid angiopathy, you did go into this a good deal. And you know, I think I encourage everybody to revisit the article to remind themselves about, you know, the findings that can increase the suspicion of tribal amyloid angiopathy. However, you also talked about transient focal neurologic episodes, which I think is just a great reminder that, you know, these can occur in this setting and definitely not to miss. Tell us more about what to look for with these types of episodes.  Dr Silbert: Transit focal neurologic episodes can be very difficult to tease apart from a transient ischemic attack. And these transient focal neurologic episodes due to CAA can present in a number of different ways. And I think the important take home message for that is that in people who have neuroimaging evidence of CAA to inform them that they are at increased risk for having these focal neurologic episodes and that if they do present to a hospital or an emergency department with any kind of neurologic event, that those treating them are aware that they have evidence of CAA on their neuroimaging because the treatment of course is quite different. So, it's someone presenting with ATIA who has transient neurologic symptoms might be considered urgently to get a thrombolytic or, you know, TPA, whereas someone who has known cerebral amyloid angiopathy or suspected CAA, they likely already have microbleeds on their neuroimaging and in those cases thrombolytics and TPA would be contraindicated and not helpful in terms of the etiology of their neurologic symptoms. Dr Grouse: That's a really good point to make. And I think also in your article you mentioned the use of aspirin if you're suspecting ATIA versus a, you know, a transient amyloid related focal neurologic episode. You know, one you would treat with aspirin and the other one you wouldn't.  Dr Silbert: That's right.  Dr Grouse: Another sort of interesting topic you delved into was cerebral microinfarct and how this can also contribute to vascular impairment. Could you elaborate a little more on that? Dr Silbert: Yeah. So cerebral microinfarcts are kind of the hidden cause of or a hidden cause of vascular cognitive impairment. And it's extremely challenging because by definition they are not visible on routine clinical neuroimaging. It's something that we are more aware of based on pathological studies and neuroimaging studies that have been done at ultra-high field strength like 7T MRI. And so, we are just learning more about how prevalent they are in certain conditions and how we can only look at these after death when we're looking at brain tissue and then go back and realize that these play a significant role in cognitive decline when someone is alive. It's important to understand that we're probably only appreciating kind of the tip of the iceberg when we're evaluating a patient and looking at their neuroimaging. That what we're actually seeing on MRI are only the things that are actually quite relatively big and obvious. And that a lot of these neuroimaging features of vascular cognitive impairment are actually associated with pathologic features that we're missing such as microinfarcts. But the hope is that by treating all individuals, particularly those who already have signs of vascular cognitive impairment, by modulating their stroke risk factors and focusing on maintaining brain health, that those will, interventions will also reduce the incidence of microinfarcts. Dr Grouse: What do you think is the greatest inequity or disparity you see in treating patients with vascular cognitive impairment? Dr Silbert: I think the greatest disparity is- really starts way before I treat a patient. That relates to really focusing on healthy lifestyle factors early in life and being able to, you know, afford fruits and vegetables, and having the advantages of being able to exercise regularly, and just being aware that all of these things are extremely important before older age. So, these are things that, you know, I think more education and awareness and greater access to healthcare will definitely improve access to. Even preventative healthcare is a disparity and not available across all of the population and geographic locations. So, I think of the- all the dementias, vascular cognitive impairment probably has the greatest association with health and social disparities in terms of primary prevention and access to care.  Dr Grouse: All really important things to consider. I have to say when, you know, reading your article, dare I say I came away with a little bit of hope thinking, you know, even with, you know, how little we still, you know, or how much we still need to do to really learn how to fight Alzheimer's and, you know, prevent it and, and, you know, help with its progression. The idea that in so many cases, even just doing what we can to prevent the vascular or cognitive impairment can really help any type of dementia. That was really a strong message for me. Do you mind elaborating on that a little more?  Dr Silbert: No, not at all. I agree. I really am hopeful about the prevention and treatment of dementias and through the treatment and prevention of cerebrovascular disease. I think that is a true reality, just like, you know, as we were discussing before, the treatment and prevention of cerebrovascular disease really should be a part of the treatment of any type of cognitive impairment and recommendations for prevention of cognitive impairment. This is the, you know, one thing we know is largely modifiable and preventable in most cases. I think the, really the key thing is just education and making sure that people understand that these are things that really need to be, they need to be engaged in in midlife and that it's much harder to reverse these- the damages once you have them in later life. Having said that, I do think that there's greater awareness of maintaining healthy lifestyle and maintaining awareness of stroke risk factors. And I think we're already starting to see a reduction in dementia worldwide in several large population-based studies, and probably that is due to more attention to the modifying stroke risk factors. So, I agree with you, it's very encouraging.  Dr Grouse: Is there anything exciting on the horizon that you can tell us about that we should all be keeping our eyes out for? Dr Silbert: Yeah. So, you know, I'm really interested in this connection between vascular cognitive impairment and Alzheimer's disease. And it's a real area of exciting new research. And so I think we're going to have more answers as to how, whether and how, cerebrovascular disease is directly linked to accumulating neurodegenerative disease or neurodegenerative pathologies. The other area that's, I think, really exciting, that's moving forward, is the in the area of blood-based biomarkers for vascular cognitive impairment. As these emerge, we'll be able to really identify those at greatest risk for vascular cognitive impairment, but also identify novel mechanisms that lead to VCI that can be targeted for therapeutic intervention. Dr Grouse: Well, I'm really excited to see what's coming down the pipeline and what more we'll learn in this area. So, thank you so much for everything you've done to contribute to this field. Dr Silbert: Yeah.  Dr Grouse: I wanted to ask a little bit more about you. What drew you to this work?  Dr Silbert: Well, actually, so my very first published manuscript in medical school was a case report and review on MELAS, which is mitochondrial encephalopathy with lactic acidosis and strokelike syndrome. And so, I was really fortunate to have Dr Jose Biller, who is a renowned expert in stroke and cerebrovascular disorders, as my mentor for that paper. And so, that got me really interested in neuroimaging findings of cerebral vascular disease. And so when I was a fellow at Oregon Health and Science University, I was then really fortunate to  be able to work with Jeffrey Kaye's oldest old population. And in working with that population, I really became interested in their neuroimaging findings of these white matter lesions and just realizing how prevalent they were in that population, you know, it just led me to start investigating their clinical significance and etiology, which kind of led me along this path. Dr Grouse: You know, Lisa, thank you so much. I really learned a lot from your article, and I think our listeners will definitely find that it was very helpful for their practice. Thank you so much for joining us. Dr Silbert: Thank you so much, Katie. It's been really fun.  Dr Grouse: Again, today I've been interviewing Dr Lisa Silbert, whose article on vascular cognitive impairment appears in the most recent issue of Continuum on dementia. Be sure to check out Continuum audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/AudioCME. Thank you for listening to Continuum Audio.

Dayton and Tristan present a classic mixed bag of topics; including Dolph Lundgren films, nostalgic Warhammer and fantasy memories, and fun facts about the Grouse bird. 

In the boreal forest, winter temperatures routinely drop to 30 degrees below zero. Birds that spend the winter in this harsh domain rely on remarkable adaptations to survive. The Spruce Grouse is one such bird. Most Spruce Grouse remain here all year. In the snow-free summer, they forage on the ground, eating fresh greenery, insects, and berries. But in the snowy winter, the grouse live up in the trees, eating nothing but conifer needles. Lots and lots of needles. Because conifer needles are both low in protein and tough to digest, Spruce Grouse grow a bigger digestive system. A grouse's gizzard, which grinds food, may enlarge by 75%!More info and transcript at BirdNote.org. Want more BirdNote? Subscribe to our weekly newsletter. Sign up for BirdNote+ to get ad-free listening and other perks. BirdNote is a nonprofit. Your tax-deductible gift makes these shows possible. 

In this episode, we delve into the recent detection of Chronic Wasting Disease (CWD) in a captive deer facility in North Central West Virginia. Commissioner of Agriculture Kent Leonhardt provides insights into the discovery and the measures being taken to contain its spread. We also discuss the state's proactive steps to combat the decline of the ruffed grouse population, featuring a conversation with WVDNR Director Brett McMillion about a new habitat recovery program aimed at revitalizing this native species. Additionally, angling enthusiasts will enjoy our segment with bass fishing expert Andy Godwin, who shares tips and experiences from West Virginia's waters. Join us for a comprehensive look at the state's wildlife management efforts and outdoor opportunities.

Steve Chindgren returns for Part 2 of his Game Hawker Edition series, and he brings along a surprise guest.  Steve gets us started by talking about the character traits of each of his birds.  We then talk about how the grouse have adjusted to the onset of winter. We then turn our attention to the effect of colder weather on pitch, and Steve shares a tip or two on how to get a bird to take a better pitch. I ask Steve when he thinks it's too cold to hawk, and we talk about cold weather weight management. Our surprise guest offers some additional insight too.  I wondered whether Steve had seen the usual influx of golden eagles since we last spoke, and he highlights some of the unanticipated problems that can occur. On this topic, our surprise guest offers an opinion on mobs, murderous mobs. Steve tells us about the various guests he has hosted at the House of Grouse this season, and then we conclude episode with our surprise guest recounting the events of a recent flight. Thanks for listening, and I hope you enjoy Steve's update.

Lindsay sees a spruce grouse on her hike.

Tim Linehan guides forest grouse hunters ... in Montana. He's been an Orvis-endorsed outfitters for over 30 years chasing ruffies, duskies, blues, sooties ... or whatever they're calling the critters these days. He'll share strategies, including how to start a hunt; tactics when a dog points; shooting advice and habitat types for each species. We also share stories on the joys of bird hunting from good shots to young dogs, and the real reasons we hunt. Great tips from a couple listeners on dog emergencies and how to avoid them; "Handle It" covers a question from Neil Higgins of Minnesota on a young dog's steadiness. And it's all brought to you by: Sage & Braker Mercantile, LandTrust.com, HiVizSights.com, Pointer shotguns, @midwayusa, #midwayusa, MidwayUSA, Mid Valley Clays and Shooting School, TrulockChokes, HiViz shooting systems, Purina Pro Plan Sport and FindBirdHuntingSpots.com. And don't miss Wingshooting USA TV airing on local stations, sports networks and national TV networks. Learn more here.

A Columbian Sharp-Tailed Grouse displaying its feathers and performing a rhythmic mating ritual. (Stephanie Galla / Boise State )Many bird species around the world are struggling, trying to adapt to a world that's changing around them, as humans encroach on their homes. The West is seeing this happen with the Columbian Sharp-Tailed Grouse, where birds can only be found on 5% of the habitat where they once roamed.“Here in Idaho we have about 30,000 birds left, a stronghold in the lower 48 states,” said Stephanie Galla. She's an Assistant Professor in Avian Biology in the Department of Biological Sciences and she's the primary investigator of the Conservation Genetics Lab at Boise State.(Stephanie Galla / Boise State University)Meanwhile in the Arctic, Gyrfalcons are getting more bird flu, as warmer weather brings more insects and disease in Alaska and Greenland. Are birds like these able to adapt to change? How can we predict if they'll be resilient enough to survive?Galla has two possible answers to these questions: DNA and a kinder approach to research.Conservation Genetics Lab at Boise State University is made up of researchers who are using DNA to map the story of bird decline.“Our lab group uses many different genetic and genomic tools to better understand the story of the diversity of birds and how they may be adapting to a changing world,” said Galla.She's been studying Columbian Sharp-Tailed Grouse and says they are a very colorful and rhythmic species. Grouse leave footprints in the snow after their mating dance.(Stephanie Galla / Boise State )“The male grouse will stomp their feet on the ground, put their wings out wide, rattle their tail, and inflate air sacs on the sides of their necks that are bright purple,” said Galla. “They also have eye combs, sort of like eyebrows, that are bright yellow. So these are incredibly charismatic birds that are found here in Idaho and one of the best dancers that you'll see.”Galla said that the grouse has seen significant decline in Idaho and Washington and it's important to study them now.“We have a really precious resource here that we can manage, and we can make sure that they stick around for as long as they can.” Stephanie Galla uses Grouse poop to identify DNA for her research.(Stephanie Galla / Boise State)Avian researchers are utilizing DNA to identify diversity in different grouse populations."We often use DNA to understand what diversity looks like to identify populations that have lower diversity and may be less resilient and in need of conservation prioritization in a changing world,” Galla explained.She said grouse DNA can be painlessly sampled through their poop.“Within a single fecal pellet, we can understand the diversity of what birds are eating and how they're responding to changing habitats over time. We can also get a good idea of their gut microbiome, or all of the diversity of microbes that live in their gut.”Galla calls it a noninvasive approach to research. “You don't need to catch a bird to find their poop. You can find it by looking at the areas where they congregate or the areas where they sleep at night, their roosting spots.” Stephanie Galla also creates illustrations many of the birds she studies.(Stephanie Galla / Boise State )Galla built a diet database of what the birds eat in Idaho and Washington.“We're really interested in seeing what the diet looks like across space and time,” she said. “We've discovered roughly 120 different plant species across their range so far.”That's important because “if we know what populations are doing well and what they're eating and how that might compare to populations that aren't doing well. We can figure out whether or not food might be a contributor to population success, or population decline, or fitness of birds over time.” Gyrfalcon chicks in Iceland.(Stephanie Galla / Boise State)Stephanie Galla and her Conservation Genetics Lab at Boise State are also studying Gyrfalcons in the Arctic and how they're adapting to a warming climate. And she's a co-founder of the Kindness in Science project, a project that started when she was in Aotearoa, New Zealand as a PhD student.“We started this initiative to define a culture where we are prioritizing diversity and maintaining diversity of people and science over space and time. Where maybe we have single individuals that are prioritized more than a group,” Galla explained.Although Columbian Sharp-Tailed Grouse are not federally threatened or endangered yet, they are currently experiencing a steep decline.“We have an opportunity here to step in and actually make a difference, make a difference so that we don't end up with just a few hundred left. If there are tens of thousands of them here in Idaho, we have an opportunity to characterize their diversity, understand it better, and work with conservation practitioners,” Galla said.Galla says studying birds in three different parts of the world can bring not only conservation efforts together, but people as well.“They give us a really great sense of wonder and connection and home,” she said. “The great part about studying DNA is that every bird has it, no matter where in the world you are, so we can take lessons learned from other countries, from other systems.”She said researchers and resource managers can apply those lessons locally in Idaho. “The more we come together as a global community with these different approaches, the better we can be equipped to address these big challenges and biodiversity loss that we're seeing around the world.” Illustration by Stephanie Galla(Stephanie Galla / Boise State )

This is the fourth episode of Pheasants Forever's 15th annual Rooster Road Trip. Host Bob St.Pierre is joined by PF's Vice President of Marketing Andrew Vavra and University of North Dakota's Dr. Susan Felege. Dr. Felege is a professor of wildlife biology & management and is also a member of PF & QF's National Board of Directors. Episode Highlights: • Dr. Felege recounts the history of prairie grouse populations across North Dakota and provides a status report for how sharp-tailed grouse and greater prairie chickens are currently doing in the state. • Vavra talks about “the pucker factor” of hunting in a region where greater prairie chickens and hen pheasants are illegal to shoot, while sharp-tailed grouse and sharpie/chicken hybrids are both legal. • Dr. Felege also shares her enthusiasm for working with the Grand Forks County Prairie Partners and how the collection of non-profit groups, state and federal agencies, farmers, and volunteers are helping conserve this very special tall grass prairie. • Find the companion video accompanying this podcast episode at www.RoosterRoadTrip.org. While there, enter to win a Browning Citori 825 shotgun and join/renew/extend your Pheasants Forever or Quail Forever membership featuring the new Browning Bird & Buck knife. And special thanks to our Rooster Road Trip 2024 sponsors • Browning • Orvis • SoundGear • Ruff Land Kennels • Federal Ammunition • Garmin • YETI • Irish Setter onX Hunt is a proud supporter of Pheasants Forever and Quail Forever and they want to thank everyone who gives back to the birds we all love to hunt and the places they call home. Click this link to get a free month of onX Hunt and then use code PFQF to get 20% off, and a portion will go back to supporting Pheasants Forever and Quail Forever's wildlife habitat mission.

Joined by Bob Owens of Lone Duck, we discuss a recent ruffed grouse hunt, a cross country bird hunting trip, bird dogs and more. Show Highlights: Duck and goose hunting the great plains Scouting for cover and access in a new state Have you ever seen the northern lights IRL? Attending the Grand National Grouse Championship in Wisconsin Scouting and exploring ruffed grouse habitat Getting a young puppy on grouse Bird dogs naturally backing or not… Nick and Bob take a walk through the grouse woods 2025 St. Hubtert's Trial - Cheraw, SC SUPPORT | patreon.com/birdshot Follow us | @birdshot.podcast Use Promo Code | BSP20 to save 20% with onX Hunt Use Promo Code | BP15 to save 15% on Marshwear Clothing Use Promo Code | BSP10 to save 10% on Trulock Chokes The Birdshot Podcast is Presented By: onX Hunt, Final Rise and Upland Gun Company Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textThis week on the Montana Outdoor Podcast your host Downrigger Dale spent an information packed hour with Montana Fish, Wildlife and Parks, Wildlife Manager for Region 2, Liz Bradley. Liz and Rigger covered it all from where to find the Elk, Mulies and Whitetail Deer to the best spots to bag some Grouse, Waterfowl and yes even, though rare for the area, the elusive Pronghorn. Liz even covered some great ideas on where to find Black Bears, Mountain Lions and more! Rigger got all the questions he could think of answered, including things like what type of hunting the region is most noted for, what the private land hunting accessibility is like, what the biggest challenges the region is currently facing and what the biggest accomplishments Liz and her crew have made recently! West-Central Montana can be an extremely successful place to hunt IF you know all the current information about the area and this Podcast is THE place to get all of that, so get to listening and then go have a successful hunt!Links:Click here to look through the FWP Big Game Hunting Forecast for Region 2.If you would like to learn more about Region 2, click here.Wildlife Manager Liz Bradley also mentioned a great report for you Region 2 Elk Hunters called the 2024 State of the Elk for Region 2. Click here to read the latest version of that report! You can also find more great ongoing updates on the Region 2 Facebook Page by clicking here! Or why not signup to get regular updates by clicking here!Click here to use the FWP Hunt Planner Map.To learn more about the FWP Region 2 Block Management Program as well as to get property maps and more for Region 2 click here.Click here to get up to date on all Montana hunting regulations.To learn how to collect a CWD sample from your harvested animal click here.Do you have questions or comments for Region 2 Wildlife Manager Liz Bradley? Click here to send her an email.Click here to send Downrigger Dale an email.Remember to tune in to our live radio show, The Montana Outdoor Radio Show, every Saturday morning from 6:00AM to 8:00AM. The show airs on 30 radio stations all across the State of Montana. You can get a list of our affiliated radio stations on our website. You can also listen to recordings of past shows, get fishing and and hunting information and much more at that website or on our Facebook page. You can also watch our radio show there as well.

Joined by Nick Adair of the Gun Dog It Yourself Podcast, we recap some recent hunts and get an update from Nick and his dogs on his multi-state ruffed grouse hunting road-trip. Show Highlights: Great Lakes grouse woods report “What seriously happened last night?” Where are all the woodcock? Making memories with aging bird dogs Puppy walks and porcupines Rooftop tents and camping set-ups  The Bird Dog Society St Huberts Trial Ruffed grouse patterns and food sources LISTEN | Gun Dog It Yourself Podcast SUPPORT | patreon.com/birdshot Follow us | @birdshot.podcast Use Promo Code | BSP20 to save 20% with onX Hunt Use Promo Code | BP15 to save 15% on Marshwear Clothing Use Promo Code | BSP10 to save 10% on Trulock Chokes The Birdshot Podcast is Presented By: onX Hunt, Final Rise and Upland Gun Company Learn more about your ad choices. Visit megaphone.fm/adchoices

Spine pain is one of the most common presenting concerns in health care settings. It is important for neurologists to understand strategies for evaluating and managing patients with spine pain. In this episode, Katie Grouse, MD, FAAN, speaks with Vernon B. Williams, MD, FAAN, author of the article “Spine Pain,” in the Continuum October 2024 Pain Management in Neurology issue. Dr. Grouse is a Continuum® Audio interviewer and a clinical assistant professor at the University of California San Francisco in San Francisco, California. Dr. Williams is the director of the Center for Sports Neurology and Pain Medicine at Cedars-Sinai Kerlan-Jobe Institute in Los Angeles, California. Additional Resources Read the article: Spine Pain Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Guest: @VernWilliamsMD Transcript Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum Journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Grouse: This is Dr Katie Grouse. Today I'm interviewing Dr Vernon Williams about his article on spine pain, which appears in the October 2024 Continuum issue on pain management in neurology. Welcome to the podcast, and please introduce yourself to our audience.  Dr Williams: Oh, well, thanks for having me. My name is Vernon Williams and I'm a neurologist here in Southern California. Dr Grouse: So, I want to start off today by asking, what do you feel is the key message from your article? Dr Williams: So, I think the key message is that we want to make sure people understand that there's really a distinction between abnormal imaging, tissue damage, nociception, and this experience of spine pain. So, the concept is that nociception is different from the clinical experience of pain; nociception, meaning the electrical signaling from these, quote unquote, pain generators and that kind of thing. But it's really an incomplete framing. We really want people to understand that the experience of pain is colored by a number of other things, things like genetics, biochemical factors, behavior and psychological factors, social factors, those kinds of things. So that's one of the big messages, this distinction between nociception and this clinical experience of pain.  Dr Grouse: Why do you think it's important for neurology clinicians to read this article? Dr Williams: Well, I think, you know, for one thing, spine pain is very common. So, it is likely that neurologists will encounter patients who come to see them because of that chief complaint. But I think that if we want to really be successful at treating spine-related pain, then we really have to know all of that basic information, the basic knowledge that we came to learn as residents and medical students or what have you. But it's also important to know that that knowledge is necessary, but it's insufficient. You really also have to confront pain from the standpoint of these other things, these other behavioral factors, psychological factors, social factors, and you got to kind of combine those things to be the most successful in treating this very common condition.  Dr Grouse: You know, you mentioned earlier about the difference between tissue damage pain and nociception. I find this to be, you know, a really great lens thinking about these concepts to view this topic and your article specifically. Can you go a little more into what the difference between, specifically, pain and nociception really is? Dr Williams: Yeah. I mean, so when we talk about nociception, in many ways we're talking about the electrical activity. And so, there's the stimulation of these nerves, in the periphery typically, and that electrical signal is transmitted, you know, from those nociceptive fibers into the spinal cord. And it's headed from the first-order neuron to the second-order neuron and axons in the spinal cord and eventually reaches the brain. But essentially the concept is that it's not pain at that point. It's not pain until those signals reach the cortex and they are experienced in some context. And that context really colors whether or not, and to what extent, people experience pain or suffer pain as a result. So, when we think about nociception, we tend to think about kind of tissue damage or the threat of tissue damage. And in clinic, we tend to kind of focus on that and we look for relationships between abnormalities on imaging studies that could be causing those kinds of electrical signals. And we tend to focus less on that second but critical aspect of things, and that's that individual 's personal experience, which is colored by a number of different things: their attention, their expectation, colored by how we interact with them, our verbal and non-verbal communication with them. And again, like we talked about: their history, who are they, their genetics, their behavioral history, their psychological history and those kinds of things. So, it's really this combination of things that we have to be aware of when we're treating spine pain. And I think the tendency is for us to focus on the first half and less on the second half. Dr Grouse: Absolutely. I certainly think our training and our focus on localizing the lesion may in some ways hurt us in that sense because we really focus so much on the first and not so much the second. Would you say that's probably right? Dr Williams: Yeah, I mean, that's part of our heritage as clinicians, particularly neurologists. It's, where's the lesion? And so, what happens when there is no, quote unquote, lesion? What happens if there are multiple potential lesions? And so, these kinds of concepts, I think, become really important, and the context in which you're examining and evaluating that patient becomes important. And I think they are at least as important as the potential pain generator or the nociceptive signal.   Dr Grouse: Now, you mentioned earlier something about sort of how we approach the patient and the language we're putting out, the body language. I found the concept of nocebo and maladaptive pain-related neuroplasticity to be absolutely fascinating when I was reading your article, and I was really surprised to learn that clinicians can really contribute to this effect unknowingly through their body language, verbal language, nonverbal messaging, and even how they're interpreting the test results? When a patient comes to see you with chronic back pain, how do you approach the whole process to minimize this effect and, really, to set the stage for more constructive and therapeutic evaluation? Dr Williams: Yeah, Katie, I think that's… it's tough because our culture is so, you know, it's so ingrained in our culture to look for a structural abnormality as an explanation for an individual 's symptoms. And so, I find myself struggling with that all the time, not only discussing why we're ordering an imaging study, but, if that person comes back and I'm describing to them the abnormalities on that imaging study, I've got to be very careful about describing them in the context of what we expect. And so, I'll typically try to use words like, well, you've got some wear-and-tear changes that we all get, as compared to saying, well, you've got a disc herniation abnormality at L five S one that's causing your pain. That statement could have a negative effect on that individual's framing of what's going on. Maybe that L five S one disc is contributing to their symptoms and maybe it isn't. Maybe it's been there or for years and maybe it's new. And even if it is new, does that mean, in that patient's mind, that now they've got an abnormality that has to be fixed or else they will continue to have pain? And so, kind of trying to keep all of those things in mind is why we want to kind of color that interaction. And I mentioned both verbal and nonverbal interaction and communication with the patient, because I think that they are picking up on all of these signals. Some of them are very obvious and some of them are very subtle. But keep in mind their brains, their nervous systems are primed to interpret all of these signals, both verbal and nonverbal. And that's going to have a downstream - or upstream, I would say - effect on their framing and how they interpret the interaction and what they think it means for them and their future. So, you know, it's kind of a big thing to think about when you- every time you walk in a room, but it's an important thing to think about when we're communicating with patients.  Dr Grouse: It's absolutely fascinating and has really made me go back and think about, gosh, are there ways that I could have done things better to really message this in a more helpful way? And on that note, do you have any tips or tricks on how to put out that that messaging, both verbal and nonverbal; to be, you know, to avoid those pitfalls of kind of reinforcing the wrong message about tissue damage? Dr Williams: Yeah. I mean, so one of the main things is trying to be very purposeful about educating people on the difference between tissue damage or potential tissue damage and pain. And so being careful not to use statements like, well, I think your pain is coming from this disc or this structural abnormality because again, we want to try to separate those things. They are different. I think that, you know, how we discuss imaging studies is very important because you want people to understand that an imaging study is just that. It's anatomy and it doesn't equal function, it doesn't equal what they experience in terms of sensory symptoms and pain. But I think the goal is to try to be very purposeful and maybe even reexamine how we discuss those things or when we discuss those things. One of the things I've found helpful is kind of the order in which I perform my clinical assessment. So traditionally, I was taught, like many, take the history, do the physical examination, and then start to discuss and educate patients. Right? Here's the test I want to order, here's what I think may be going on, so on and so forth. I think in some cases it's more beneficial to take the history and, before the physical examination, discuss what I'm thinking, taking that opportunity to discuss the differences between nociception, tissue damage, the experience of pain, the importance of movement, so on and so forth. And then do the physical examination so that that person has some idea of what is it that he's looking for. How is this going to inform his opinions and recommendations and so on and so forth. But also provide them with the concept that movement, for instance, is safe unless they have certain kinds of red flags on their history. I'm encouraging movement and I'm encouraging them to recognize that some of these movements they may have predicted would have been painful for them actually aren't painful, and they may start to internalize the concept that they can do it once without paying, that probably means that they're not damaging themselves every time they perform that movement. And if they can do one pain-free rep, that's important, and that may counteract the concept that they are damaging themselves every time they move and every time they feel pain, that means that there's tissue damage. So, what we talk about, how we talk about it and even when we talk about it during the course of that evaluation may have some negative or positive effects. And it may be beneficial to kind of think about those things and whether or not our typical approach might be the best or maybe we can improve on that or adjust that, particularly in certain situations and with certain patients. Dr Grouse: That's absolutely fascinating, and great tips I think that all of our listeners will want to incorporate as we're approaching this patient population. You know, in your article, I also wanted to talk about, you mentioned some really interesting treatments for pain is that I think would include, or would, fall under the category of neuromodulation. Can you summarize some of these options for us? Dr Williams: Yeah. I mean, so I think that the concept of neuromodulation, I tend to think of it in a very holistic sense. And so not only focusing on the application of external stimuli and that could be, you know, electrical stimuli, magnetic stimuli, cryo, analgesia, those kinds of things in order to turn up or down nervous system activity, electrical signals, what have you. I think of neuromodulation in a global sense. I think in a way, cognitive restructuring and education, in a way, is a form of neuromodulation. It's affecting how that individual frames the concept of their pain, structural changes versus experience, so on and so forth. But generally, I'm talking about these kinds of things. So, there are some very interesting approaches with electrical stimulation and it doesn't necessarily have to be permanent implantation of a stimulator as we tend to think about with spinal cord stimulation, but there are some interesting temporary peripheral nerve stimulators that that can be very helpful for various kinds of spinal pain. And then there's also these technologies that I find fascinating. Some of them are in the wearables category. So, combining the education and framing and cognitive restructuring with things like virtual reality, there are some interesting programs that combine some predictive modeling with virtual reality, such that an individual has goggles on, they are participating in some activity that requires them to move in a certain direction and move to a certain extent that may or may not match what they are seeing visually in the goggles. So, you can kind of begin to kind of dissociate their expectation of when they may experience pain as a function of their movement from what actually happens. So, these kinds of things, I think, are really interesting ways to augment our traditional approaches to pain, physical therapy, rehabilitation, medications, some kinds of injections, with these additional approaches that really have an effect on the nervous system as opposed to just focusing on what I would call kind of the mechanical anatomy, the joints and the discs and what have you, with traditional approaches. Dr Grouse: It's really exciting to hear about some of these new options that can be tried to help with this neuromodulation and sort of cognitive restructuring. Of course, understanding that there's some things that we do ourselves that do this in the clinic encounter, which I think is a great reminder. I wanted to touch on, in your article, you had mentioned that we really have to be aware as clinicians, that health inequities and disparities and even the social determinants of health have inevitable effects on spine pain. How can our listeners better recognize and ensure equitable care for this patient population, particularly in light of the fact that many of these therapies that we've just been talking about can be difficult to access even in the best circumstances? Dr Williams: Well, you know, thanks for asking that question. I think that's a great question. I think from the standpoint of, you know, health equity and addressing, you know, disparities and that kind of thing, the first thing is to just acknowledge and recognize that these things are present. And even, you know, though we may have the best intentions, there may be scenarios where our practices are affected and our patients are affected by these kinds of things. So, I think the first thing is the acknowledgement. And then the second thing is kind of trying to figure out if there are things that we can do as individual practitioners, or our offices can do or the entities that we interact with, maybe that's a hospital system or what have you to address these kinds of things. So, we know, for instance, from the standpoint of race and ethnicity, there's disparities with respect to African Americans, with Hispanics and other ethnic minorities and the kind of care they receive. We know that access resulting from insurance coverage and geographical limitations, that kind of thing can be significant. And interestingly, it doesn't necessarily mean that the person is uninsured. So, for instance, we will often see individuals who've had work injuries and who are covered by the workers' compensation system have certain limitations placed on what they have access to, often resulting in lots of frustration from those patients. And that's a reality that we sometimes have to work really hard to overcome. Socioeconomic status, provider bias. And again, this is something that we have to kind of do some internal searching to say, hey, am I approaching these individuals on a on a more equal and equitable basis, or am I also subject to some of the biases that that I've been exposed to and trying to overcome that? So, I think that's a huge part of the context. And when we talk about how we learn, whether we're talking about spine pain or anything else, I'm a believer in that kind of cycle of pedagogy that includes content-based information, which is kind of the very basic foundational information, that includes things we can memorize and definitions we can memorize. And that may include things like what we've talked about relative to kind of the nociception and pain pathways, so on and so forth. But then there are concepts, and we've talked about the concept of verbal communication and nonverbal communication, the concept of cognitive restructuring and neuromodulation as an approach. But then context is kind of that last level, probably the most significant level in terms of how we can integrate all this information and really master information. And that context has to do with things like social determinants and disparities and the reality that these things have an effect on how we evaluate and manage patients and the success with which patients can be managed. And so, I appreciate that question, I think it's a great question, because it gets that kind of the reality of what does this look like in real life as opposed to just on the page or just in a textbook. Dr Grouse: Well, that's really helpful and certainly something that we can all keep in mind as we try to be more aware of this, and I like the idea of just acknowledging it and just having it there, knowing that this exists and helping that inform how we approach these patients. I wanted to ask you, what do you think the biggest controversy is currently in the evaluation and management of spine pain? Dr Williams: You know, I think that there's a couple of controversies that are interesting. Nowadays, one of them has to do with the utility of some of the things that have been performed and done most frequently for spine pain, and that's things like epidural injections, facet injections, some of the interventional procedures. There's some controversy among some as to whether or not these things are effective, you know, what role they have in treatment because some people will say, oh, is there any long-term effect from these kinds of procedures? Even patients will sometimes say, hey, listen, I'm not sure if I want an injection because isn't that just temporary, or, isn't that just a band aid? But I think that when we talk about pain from the perspective of it potentially being a progressive disorder and trying to be aggressive with managing pain so that we are less likely to see some of the chronic manifestations that occur with maladaptive neuroplasticity it's important to be aggressive with stopping no subceptive signals, reducing an individual 's experience of pain, optimizing their function, and having a positive effect on the ability to treat and eliminate pain, even if that means with epidural injections or blocks or what have you, as long as they're safe and effective. I think that there are some controversies evolving related to some of the regenerative procedures that have been done for other kinds of musculoskeletal pain. So, for instance, PRP and stem cells, you know, people have been doing those for knees and muscle tears and what have you. And of course, that technology has kind of evolved into potential approaches for spine pain. People are often interested in whether PRP or stem cells may help their spine pain. And so, I think that's another area of potential controversy because there hasn't been a ton of, you know, high-level evidence, although there are some, you know, there's some studies out there and there's some evidence that they may be of benefit. And I think the role of stimulators and implants for axial pain is another area of potential controversy. Those are probably the biggest things in this area of spine pain that are topics of controversy. There are things that have people talked about for years in terms of chiropractic care versus traditional medical care. But I think right now it's the utility of these kinds of interventional procedures, the role of regenerative procedures and injections, and then the role of more aggressive interventions like permanent implantation of stimulators and that kind. Dr Grouse: Is there anything coming on the horizon in the field of managing spine pain that we should be looking out for? Dr Williams: Well, you know, I am still bullish on the concept of neuromodulation and we've talked about that peripheral nerve stimulation, spinal cord stimulation, and then other wearables, VR, so on and so forth. I think that those things will continue to evolve, and I think that technologies continue to evolve that are likely to help with spine related pain. Some of them are very interestingly related to the ability to strengthen multifidus muscles and improve muscular function in individuals with spine pain. But I think that's one area - neuromodulation - that we'll continue to see evolution. I think that- I'm interested to see what the role of regenerative injections and regenerative procedures may play. And then just like every other field of human endeavor, artificial intelligence, machine learning, those kinds of things are likely to have a significant effect on how we diagnose an individuals, on treatment options for various individuals, and even a predicting outcome from various treatment. So those, I think, are examples of areas that we'll see continued growth and evolution with respect to spine pain. Dr Grouse: Well, I'm very excited to see what comes down the pipeline and both vastly more to come, I'm sure. So, thank you so much, Vernon, for joining us. I really enjoyed reading your article. I really enjoyed talking about this topic. I think I've learned a lot and I hope that our listeners will take the time to read this article. It's really, really helpful. Dr Williams: Well, I appreciate the opportunity. I really enjoy participating in this process. The interview was fun, so thanks a lot for having me. I really appreciate it. Dr Grouse: Again, today I've been interviewing Dr Vernon Williams, whose article on spine pain appears in the most recent issue of Continuum on pain management in neurology. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at Continnpub.com/AudioCME. Thank you for listening to Continuum Audio.

Send us a textThis week on the Montana Outdoor Podcast your host Downrigger Dale talks to Montana FWP Wildlife Manager Cory Loecker to find out what the hunting will be like in North Central Montana Region 4. Cory and Rigger covered that region inside and out and Cory gave information on how healthy the Elk, Deer and Antelope herds are as well as where the best places are to find them. Spoiler Alert: Things are looking pretty darn good for those! But Cory dished out even more! He went over the outlook for success if you want to hunt Black Bear, Mountain Lions, Waterfowl, Pheasants and all kinds of other Upland Game Birds. Heck he even covered what the hunting outlook was for Turkeys and yes even Wolves and more! In other words if it runs, flys, creeps, crawls, stocks, sneaks or anything else in North Central Montana, he covered it! This podcast is basically a treasure trove of information for any hunter that wants the most up to date information to increase their hunting success no matter what they want to hunt in North Central Montana! This Podcast FOR SURE needs to be on your playlist if you want to be ahead of all the rest of the hunters in that region. So could this Podcast get any better? YES and it is! Rigger and Cory also talked about hunting access, what the main challenges are for the region and even what the top successes Cory and his crew have had in improving the wildlife management in Region 4! In fact Downrigger got a little personal with Wildlife Manager Loecker and even got him to spill the beans on what his favorite game is to hunt. So what are you waiting for? Get to listening!!Links:Click here to look through the FWP Big Game Hunting Forecast for Region 4.If you would like to learn more about Region 4, click here. You can also find more great ongoing updates on the Region 4 Facebook Page by clicking here!Click here to use the FWP Hunt Planner Map.To learn more about the FWP Region 4 Block Management Program as well as to get property maps and more for Region 4 click here.Click here to get up to date on all Montana hunting regulations.To learn how to collect a CWD sample from your harvested animal click here.Do you have questions or comments for Region 4 Wildlife Manager Cory Loecker? Click here to send him an email!Questions for Downrigger Dale? Remember to tune in to our live radio show, The Montana Outdoor Radio Show, every Saturday morning from 6:00AM to 8:00AM. The show airs on 30 radio stations all across the State of Montana. You can get a list of our affiliated radio stations on our website. You can also listen to recordings of past shows, get fishing and and hunting information and much more at that website or on our Facebook page. You can also watch our radio show there as well.

After a week in Canada's bush country, Ben Brettingen & George Lyall sit down with Travis Frank to share stories from their remote wilderness ruffed grouse hunting adventure based out of Sunset Channel Outpost on Lake of the Woods.  The trio share laughs, struggles, lessons learned, success stories, tips to find ruffed grouse in the upper Midwest, going remote, catching walleyes from shore, hunting waterfowl between grouse flushes, recipes from camp, reasons to plan a true adventure, and so much more… @benbrettingen @g.lyall66   Presented by: Walton's (https://www.waltons.com/) OnX Maps (https://www.onxmaps.com/) Aluma Trailers (https://www.alumaklm.com) Chief Upland (https://chiefupland.com/) Lucky Duck Premium Decoys (https://www.luckyduck.com/) Federal Premium Ammunition (https://www.federalpremium.com/) Sage and Braker (https://sageandbraker.com/) Hunt North Dakota (https://www.helloND.com/)  

After a week in Canada's bush country, Ben Brettingen & George Lyall sit down with Travis Frank to share stories from their remote wilderness ruffed grouse hunting adventure based out of Sunset Channel Outpost on Lake of the Woods.  The trio share laughs, struggles, lessons learned, success stories, tips to find ruffed grouse in the upper Midwest, going remote, catching walleyes from shore, hunting waterfowl between grouse flushes, recipes from camp, reasons to plan a true adventure, and so much more… @benbrettingen @g.lyall66   Presented by: Walton's (https://www.waltons.com/) OnX Maps (https://www.onxmaps.com/) Aluma Trailers (https://www.alumaklm.com) Chief Upland (https://chiefupland.com/) Lucky Duck Premium Decoys (https://www.luckyduck.com/) Federal Premium Ammunition (https://www.federalpremium.com/) Sage and Braker (https://sageandbraker.com/) Hunt North Dakota (https://www.helloND.com/)  

What makes an ideal grouse gun, or what Gene Hill would call “a gun of specialist function?” Does action type matter? What about gauge? How does the environment play into it? How has the modernization of gun-making changed grouse guns? How different is a grouse gun from a clays gun? How different is a gun built for ruffed grouse hunting versus shotguns used for other wild game? While I don't have all the answers, I do have theories. Like any evolving tradition, they're built on the backs of those who came before me.

Joined once again by Ann Jandernoa we answer listener questions on all things grouse and woodcock hunting during part two of our annual conversation. Show Highlights: How might wet spring conditions affect grouse nesting and brooding? Checking rainfall amounts in your area - VegDRI Index Hunting pressured grouse Do woodcock run more than they used to? What kind of hunting boots do you like?  Check out the Hunt the Habitat Podcast Binge listen to Ann on grouse and woodcock: 2017 - Episode #7 2018 - Episode #42 2019 - Episode #76 2020 - Episode #115 2021 - Episode #150 2022 - Episode #190 2023 - Episode #239 and #240 2024 - Episode #289 MAP | with Scout N Hunt SUPPORT | patreon.com/birdshot Follow us | @birdshot.podcast Use Promo Code | BSP20 to save 20% with onX Hunt Use Promo Code | BSP15 to save 15% on Marshwear Clothing Use Promo Code | BSP10 to save 10% on Trulock Chokes The Birdshot Podcast is Presented By: onX Hunt, Final Rise and Upland Gun Company Learn more about your ad choices. Visit megaphone.fm/adchoices

Generally speaking, grassland grouse are not the most adaptable critters. Both prairie chicken species need large expanses of grassland, while sage grouse must have large expanses of sagebrush to thrive. The one exception to this rule is the sharp-tailed grouse.  While generally considered a grassland species, sharpies range from the shrub-scrub grasslands in Wisconsin through the vast prairies of the northern U.S. Great Plains and Canada, culminating in the shrublands of Alaska. That's a huge geographic range, encompassing a wide variety of habitats, meaning there are lots of plants that are important to sharptails. That said, some plants stand out above all others, and they are found and utilized across most of this bird's vast range. 

Send us a textThis week on the Montana Outdoor Podcast your host Downrigger Dale talks with FWP Region 5 Wildlife Manager Matt Ladd about what the hunting opportunities will look like this year in his region. Matt and Rigger take a deep dive into Region 5 to discover which hunting districts in the region have the best hunting opportunities for Elk, Whitetail Deer, Mule Deer, Antelope, Waterfowl, Upland Game Birds including Pheasants and Turkeys and more! When you listen to the podcast you will find out all kinds of super useful information about animal population sizes throughout the region, how much of Region 5 has public hunting opportunities, how much of it has private land that is open to hunters through the Block Management Program and the list goes on and on. If you love to hunt in Region 5, have ever thought about hunting there or are just looking to explore other areas of the Big Sky Country to hunt in then you need to listen to this Podcast! If you do you will be WAY ahead of all the other hunters with the excellent information Matt Ladd delivers just for you! And don't miss next week's Podcast when Rigger brings you all that info for Region 6! There will be more regions to discover in the weeks that follow as well so keep checking back right here on the Montana Outdoor Podcast! Yeah, this year all you Podcast Listeners will be the best prepared hunters in the State!Links:Click here to look through the FWP Hunting Forecast for Region 5.If you would like to learn more about Region 5 click here. You can also find more great ongoing updates on the Region 5 Facebook Page by clicking here!Click here to use the FWP Hunt Planner map.To learn more about the FWP Region 5 Block Management Program as well as to get property maps and more for Region 5 click here.Click here to get up to date on all Montana hunting regulations.Do you have questions or comments for Region 5 Wildlife Manager Matt Ladd? Click here to send him an email.Don't forget your old buddy Downrigger Dale! He would love to hear your comments about this Podcast and any of your ideas for topics for future Podcasts. Just click here to send him an email.Remember to tune in to our live radio show, The Montana Outdoor Radio Show, every Saturday morning from 6:00AM to 8:00AM. The show airs on 30 radio stations all across the State of Montana. You can get a list of our affiliated radio stations on our website. You can also listen to recordings of past shows, get fishing and and hunting information and much more at that website or on our Facebook page. You can also watch our radio show there as well.

Joined once again by Ann Jandernoa we answer listener questions on all things grouse and woodcock hunting during part one of our annual conversation. Show Highlights: Saunas and white walkers in the northwoods?! Check out the Hunt the Habitat Podcast Did you say giant cinnamon rolls?! Early season habitat Running dogs in the heat Ruffwear Swamp Cooler vest Breaking down the aspen cut The importance of shrub layer - Hazel brush Maples, buckthorn and more… Binge listen to Ann on grouse and woodcock: 2017 - Episode #7 2018 - Episode #42 2019 - Episode #76 2020 - Episode #115 2021 - Episode #150 2022 - Episode #190 2023 - Episode #239 and #240 MAP | with Scout N Hunt SUPPORT | patreon.com/birdshot Follow us | @birdshot.podcast Use Promo Code | BSP20 to save 20% with onX Hunt Use Promo Code | BSP15 to save 15% on Marshwear Clothing Use Promo Code | BSP10 to save 10% on Trulock Chokes The Birdshot Podcast is Presented By: onX Hunt, Final Rise and Upland Gun Company Learn more about your ad choices. Visit megaphone.fm/adchoices

Sage-grouse need large, connected, and mostly treeless swaths of sagebrush to survive. Without this, sage-grouse cease to exist. It's that simple. Sage-grouse are what scientists and biologists call a sagebrush obligate species. You can't have sage-grouse without sage. Sage-grouse occupy western sagebrush (Artemisia sp.) prairies of California, Nevada, Oregon, Washington, Idaho, Utah, Colorado, Wyoming, Montana, North Dakota, South Dakota, and into the province of Saskatchewan. Although sage-grouse still live in all these places, their populations have shrunk. The largest core populations still thrive in Montana, Wyoming, Idaho, Nevada, and Oregon. Uncoincidentally, these are the same states with the most intact and healthy sagebrush landscapes.

Man alive! What a trip! On our last night of the Grouse tour all of us sat down to recap the highs and lows of our trip.  Central Montana was lousy with birds this year and boy did we need it after chasing mountain birds. There were plentiful numbers of Sage Grouse. The best numbers of Huns and Sharptails that I have ever seen in the country. And we even found a rattlesnake and lived to tell the tale! Presented by OnX Hunt Boss Shotshells Final Rise Dogtra Waltons Gun Dog Grind Coffee NutriSource Pet Food

Each September, an inexplicable reverence stirs within me as I patiently await the chance to roam Wyoming's boundless public lands in pursuit of the bird that holds my heart—the iconic sage grouse. There's something almost spiritual about stepping into the vast sea of sagebrush and feeling the landscape's timeless pull.  For many hunters, pursuing these majestic birds is a rare, once-in-a-lifetime adventure, often meticulously planned months or years ahead. Preparation and knowledge are key in order to appreciate and succeed in this journey. Sage grouse populations stretch across eleven western states—Wyoming, Colorado, Utah, Nevada, California, Washington, Oregon, Idaho, Montana, North Dakota, and South Dakota. Yet only seven states still permit sage grouse hunting, and season lengths and bag limits are carefully controlled.

Well boys and girls it aint easy out west! This hunt has been a good reminder that not every day is easy. In fact day 1 of this hunt was brutal. But we kept after it and found some birds. But if we were finding birds or not we still loved every minute of it.  OnX Hunt  Final Rise Boss Shotshells NutriSource Petfoods Dogtra Gun Dog Grind Coffee Waltons

A celebration in the woods! Its the kickoff for Michigan grouse season. If you want to learn what it takes to hunt grouse, or just want to hang out with a bunch like minded folks, this ones for you!

Host Bob St.Pierre is joined by Pheasants Forever Editor Tom Carpenter and Quail Forever Editor Ryan Sparks for a conversation with professional dog trainer Clyde Vetter, who also happens to be husband to PF & QF President and Chief Executive Officer Marilyn Vetter. Each member of this conversation also considers themselves prairie grouse hunting junkies, so they provide a forecast for the 2024 sharp-tailed grouse and greater prairie chicken hunting season and weave their hunting tips into a game of Prairie Grouse Battleship. Episode Highlights: • The group plays four rounds of “Prairie Grouse Battleship” in which each participant provides a fresh hunting tip for sharpies and/or chickens in hopes of scoring points for tips the other competitors don't have on their lists. • This episode marks the introduction of the brand new “Premium Moments in the Field” stories from Grain Belt Premium, “The Pheasant Friendly Beer.” • Check out the state-by-state prairie grouse hunting forecast at www.PheasantsForever.org/Primer presented by Sportsman's Guide. onX Hunt is a proud supporter of Pheasants Forever and Quail Forever and they want to thank everyone who gives back to the birds we all love to hunt and the places they call home. Click this link to get a free month of onX Hunt and then use code PFQF to get 20% off, and a portion will go back to supporting Pheasants Forever and Quail Forever's wildlife habitat mission.

In this episode of NDO Podcast we visit with Jesse Kolar, Department upland game management supervisor, about the state of our four grouse species, an additional sharp-tailed grouse hunting opportunity open this year and our favorite upland game bird recipes.

Spruce grouse are not often–if ever–regarded as the King of the Uplands. They suffer a perception forced upon them by those of us accustomed to pursuing ruffed grouse, ring-necked pheasants, sharp-tailed grouse, chukar, or any of the various quail species that inhabit our countrysides. They are renowned for their dim-wittedness, weak flush, and poor culinary experience. They've even earned the nickname “Fool Hen,” a moniker that is both well-earned and undeserved. Spruce grouse are so prevalent in Alaska that it can be easy to assume a person can simply go out and shoot one. I know because I've set out with that mindset and returned with empty game bags. They may not be the greatest challenge presented to an upland hunter, but if you don't give them their due diligence, they can easily have you leaving the woods with spent shells and unanswered questions.

Daniel Buitrago & Brandon Fifield sit down with BHA (Back Country Hunters & Anglers) Alaska Chapter coordinator Mary Glaves and local board member Sarah Dalton-Oates to discuss the latest & greatest going on with BHA Alaska!   Favorite alaskan beer, Alaska Brewing “Wild-Ness” Public land pale ale, Forbidden Peak Brewery, Pink Boots initiative, dip netting chaos, over harvest message, Hooters Season, Grouse hunting, Sarah Dalton-Oates becoming a board member w/BHA, invasive species removal in kodiak, Mary's Muskox harvest, Mary's intro, history and background, Lidar work, getting hired on w/BHA, spread Hunters & Angler Brooks Range Initiative, BHA Ambler Road victory, Tongas rainforest awareness, Juneau/Douglas new bridge access, Stevie Gawrlyuk badass in Juneau, Women bare to entry into the outdoor world, ladies range day, hunting trips, BHA Armed forces Initiative   Visit our Website - www.alaskawildproject.com Follow us on Instagram - www.instagram.com/alaskawildproject Watch the show on YouTube - www.youtube.com/@alaskawildproject $upport the show on Patreon - www.patreon.com/alaskawildproject

Interested in improving your property for ruffed grouse or American Woodcock? Tune in as we travel north and chat about all things grouse and woodcock with Jon Steigerwaldt, Great Lakes and Upper Midwest Region Forest Conservation Director from the Ruffed Grouse Society.  Topics include: grouse ecology and habitat, woodcock ecology and habitat, grouse as bellwethers for healthy forests, forest ecology of the Great Lakes states, forestry, forest management, habitat management for grouse and woodcock, grouse and woodcock habitat fundamentals, boutique forestry, and more. Jon Steigerwaldt - https://ruffedgrousesociety.org/author/jon-steigerwaldt/  Give us some feedback or potential topics you would like to here by filling out our listener survey: https://purdue.ca1.qualtrics.com/jfe/form/SV_5oteinFuEzFCDmm

Jon Steigerwaldt from RGS gives us the latest and greatest from the progress made managing our woodlands. We talk logging we talk burning and we talk about what it takes to keep our forests healthy. We also talk a bit about.... our dogs!!

This week, Cal talks animal behavior in the total eclipse, auction house, corner crossing, grizzly reintroduction and the crime desk. Connect with Cal and MeatEater Cal on Instagram and Twitter MeatEater on Instagram, Facebook, Twitter, and Youtube Shop Cal's Week in Review MerchSee omnystudio.com/listener for privacy information.